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ABSTRACT
Methamphetamine (MA) neurotoxicity is particularly evident in the striatum where it causes
extensive dopamine (DA) release and results in neurodegeneration. To identify specific signaling
pathways and macromolecules involved in postsynaptic DA-induced striatal toxicity we used a
SK-N-MC cell model that mimics postsynaptic D1 receptor-expressing striatal neurons. The cells
were treated for 6-24 h with 0-50 µM DA. The concentration was chosen to impart
physiological relevance to the study as it mirrors [DA] found within the striatum following MA
exposure. We show that 25-50 µM DA resulted in protein changes consistent with
nitro(oxidative) stress as well as enhanced cleavage of caspase (CASP) 9, CASP 3, and poly
(ADP-ribose) polymerase (PARP). Despite elevated MnSOD protein there was not increased
enzymatic activity. Examination revealed that MnSOD was nitrated following DA treatment.
Exogenous pretreatment with polyethylene glycol superoxide dismutase, an antioxidant,
prevented PARP cleavage. These results suggest a detrimental role for DA-induced reactive
oxygen/nitrogen species (RO/NS). To differentiate the D1-mediated from D1-independent effects
of DA-stimulated signaling and toxicity, the cells were treated with 0-50 µM SKF-38393, a D1
agonist; or pretreated with 10 µM SCH23390, a D1 antagonist. Both treatments resulted in
significant PARP cleavage versus control, although D1 blockade was protective when compared
to DA alone. Despite significant PARP fragmentation, treatment with the D1 agonist did not
result in significant CASP3 cleavage suggesting D1 stimulation led to apoptosis in a manner
independent of CASP3 activation. The MAP Kinase p38 was phosphorylated following D1
stimulation as well as D1-independent DA treatment. Inhibition of p38 with 2 µM SB203580
exacerbated CASP3 cleavage following D1 activation, but attenuated CASP3 and PARP
fragmentation after D1 blockade. The contradictory results of p38 phosphorylation on CASP3
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suggest that its mechanism of activation alters its downstream signaling from CASP3
stabilization to CASP3 fragmentation; thus, we have named p38 the “molecular switch” in this
system. We assessed AP-1 reporter activity as it is a downstream target of p38 and a regulator of
cell-life and –death. AP-1 transfected cells pretreated with a D1 antagonist had similar luciferase
activity as DA, while stimulation of the D1 receptor did not enhance the reporter. Pretreatment
with a p38 inhibitor reduced AP-1 activity, and AFos-, a cFos dominant negative, transfected
cells eradicated PARP cleavage. The findings indicate that DA-induced AP-1 is a D1independent, p38-mediated, cFos-dependent apoptotic pathway. We hypothesize that DA
increases RO/NS and alters redox-sensitive signaling mechanisms which result in apoptosis; and
by 1) blocking D1- together with p38-activation, 2) inactivating AP-1, or 3) providing
antioxidants we can prevent DA-mediated apoptosis that is stereotypical of MA-induced
neurodegeneration.
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CHAPTER 1
LITERATURE REVIEW
(Meth)amphetamine Abuse, Pharmacology, and Long-Term Consequences
The use of amphetamine-type stimulants (ATS) has been one of the most severe worldwide drug problems for the past 20 years. The recent upsurge in the abuse of prescription
stimulants such as amphetamine salts, dextroamphetamine, and methylphenidate—known as
“smarty drugs”; and cathinone derivatives such as mephadrone, methylone, and methedrone—
known as “bath salts,” have only compounded the problematic issue in the United States (The
United Nations Office on Drugs and Crime, 2012). Amphetamine type stimulants cause an
initial release of DA in cultured cells (Sulzer et al., 1995), rodents (Cass et al., 1989; Heikkila et
al., 1975; Schmidt et al., 1985), non-human primates (Finnegan et al., 1982; Preston et al., 1985),
and humans (Drevets et al., 2001; Laruelle et al., 1995). The elevation of DA leads to feelings of
euphoria, motivation, and alertness that initially drive the desire to consume ATS. The brain’s
limbic system is responsible for these so-called “reward” feelings, and the main anatomical
structures involved lie within the striatum of the brain, in particular a portion of the ventral
striatum known as the nucleus accumbens. Dopaminergic neurons, both those that release DA
and those that express DA receptors, exist in high concentration within the striatum. It is here
that, in addition to feelings of reward, ATS-induced neurodegeneration is prevalent (reviewed in
Volkow et al., 2004).
A variety of in vitro and in vivo models show that all ATS are neurotoxic due, at least in
part, to their resultant DA surge (Harvey et al., 2000; Preston et al., 1985; Volkow et al., 2004).
The pharmacokinetics of methamphetamine (MA; see Figure 1) causes ultra-supraphysiologic
concentrations of striatal DA that far exceed those of other ATS, and this lends MA markedly
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more neurotoxic than any stimulant (Derlet et al., 1990; Fowler et al., 2008; Volkow et al.,
2010). Indeed, neither MA itself nor its metabolites are the cause of its neurotoxicity, but MA’s
ability to cause such a substantial rise in DA concentration is (reviewed in Krasnova & Cadet,
2009). Methamphetamine, as the name suggests, shares the same structural backbone as
amphetamine (AMPH) with the addition of an amino methyl group (see Figures 1 and 2).
Methylation of AMPH’s amino group provides enhanced lipid solubility and basicity (pKa
~10.4) and facilitates greater diffusion of MA across the blood brain barrier when compared to
AMPH or other ATS (Albertson et al., 1999; Barr et al., 2006). Additionally, MA has a longer
elimination half-life once in the brain than other stimulants. For example, cocaine has a CNS
half-life of 1-3 h vs 8-30 h for that of MA (the half-life of MA largely varies based on urine pH;
Derlet et al., 1990; Fowler et al., 2008; Volkow et al., 2010). When the lingering and potent
effects of acute MA are exposed to the striatum, DA concentration within the synaptic cleft is
drastically increased through the following mechanisms: 1) inhibition of DA re-uptake by
blockade of dopamine transporters (DAT), 2) reverse transport of cytosolic DA into the synaptic
cleft, 3) impaired monoamine oxidase-dependent metabolism of DA, 4) hampered activity of
vesicular monoamine transporters, and 5) upregulation of tyrosine hydroxylase—the ratelimiting enzyme in DA synthesis (reviewed in Barr et al., 2006).
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Figure 1: The Structures of Methamphetamine (top) and Amphetamine (bottom)
A comparison of the structural similarities and differences between methamphetamine (MA) and
amphetamine (AMPH). The terminal methyl amine group within MA affords the compound
higher lipid solubility and basicity than AMPH. These biophysical properties make MA more
favorable for both diffusion across the blood brain barrier and entry into neurons than AMPH.
The neurotoxic effects of MA use have been well documented in human and rodent
models. Moderate methamphetamine abuse has been shown by functional magnetic resonance
imaging to cause regional gray matter neurodegeneration that is equal to that seen in early
dementia and greater than that caused by schizophrenia in human subjects (Thompson et al.,
2004). There is also a significant decrease in DA transporters (Wilson et al., 1996; Volkow et
al., 2001a) and D2 receptors (Volkow et al., 2001c) following human exposure to MA.
Diminished striatal concentrations of DA (Finnegan, et al., 1982; Villemagne et al., 1998) and
serotonin (Woolverton et al., 1989) as well as decreased tyrosine hydroxylase activity (Harvey et
al., 2000; Preston et al.; 1985) also occur in non-human primates after chronic MA
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administration. Prolonged abstinence from MA in primates (Fischman & Schuster, 1974; Seiden
et al., 1976) and humans (McCann et al., 1998; 2008; Volkow et al., 2001a) for up to 6 months
and 3 years, respectively, does not significantly reverse striatal DA depletion or DAT loss.
These findings indicate that MA-induced structural neurotoxicity is not reversible, even after
three years of abstinence. Additionally, performance scores on neuropsychological and
psychomotor assessments, executive functioning, and short-term memory are not significantly
improved following 12-17 months of MA abstinence, suggesting compromised functionalcognitive sequelae of MA neurotoxicity (Chang et al., 2002; McCann et al., 2008; Volkow et al.,
2001a, b). There are behavioral alterations, such as deficient attentional control and abnormal
conflict adaptation in abstinent MA users’ brains. These alterations are linked to neurochemical
brain changes in MA users that are not seen in control groups (Salo et al., 2005; 2007).
Possessing attentional control and conflict adaptation skills are pivotal in decision-making and
impulse control, thus their absence in MA users leads to cognitive impairment that is associated
with, and may even predict, drug-seeking behavior and relapse (Vanderschuren et al., 1999). It
is of paramount importance, therefore, to: 1) identify potential causes of MA-induced neurodegeneration and –toxicity, and 2) aim to combat the structural and functional damage sustained
by the brain following MA use that would provide addicts with a better chance of recovery and
abstinence.
Regional Neurotoxicity of Methamphetamine in the Striatum: Implications for Dopamine
and the Dopamine D1 Receptor
Various regions of the brain are targets of MA toxicity. A few of those areas are
particularly susceptible to MA-induced damage, especially the striatum, which is located within
the basal ganglia. This area has an abundance of pre- and postsynaptic dopaminergic neurons.
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Acute administration of MA causes DA release that stimulates DA receptors, undergoes
autoxidation, forms reactive oxygen/nitrogen species (RO/NS), and initiates a myriad of
signaling events that all result in dopaminergic neurotoxicity (reviewed in Chan et al., 2007;
Krasnova & Cadet, 2009). Chronic use of MA ultimately causes degeneration of pre-synaptic
terminals that result in striatal DA depletion and reduction of tyrosine hydroxylase activity
(Ares-Santos et al., 2013). Unlike idiopathic Parkinson’s disease where only the dopaminergic
cell bodies are damaged, MA-induced neurodegeneration occurs at presynaptic nerve terminals
and postsynaptic cell bodies where the increase in DA concentration is most abundant (Mirecki
et al., 2004).
Five known G protein-coupled receptors compose the subgroup of DA receptors. The
five subtypes are further sorted into a family of receptor-type depending if the G protein
associated with the DA receptor is a stimulator or inhibitor of adenylyl cyclase activity when
exposed to DA. The prototype stimulatory DA receptor is the D1 receptor. The D5 receptor also
belongs to the D1 family as it too is stimulatory when activated by DA. The prototype inhibitory
DA receptor is the D2 receptor. Dopamine receptors D3 and D4 belong to the D2 family. The DA
D1 receptor is the most widespread and most expressed receptor in the brain. The DA D1
receptor is heavily expressed in the striatum, nucleus accumbens, and other areas of the basal
ganglia. The DA D2 receptor is also found in the striatum and nucleus accumbens, but is rarely
co-localized with D1 receptors (Missale et al., 1998). Historically, landmark studies involving
substance addiction and neurotoxicity focused primarily on DA D2 receptors and their receptorexpressing neurons. The availability of [11C]raclopride and other radioactive DA D2 ligands
made positron emission tomography studies of DA D2 receptors popular in the examination of
addiction pathology and neurotoxicity (McCann et al., 1998; Morgan et al., 2002; Volkow et al.,
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2001a; b; c; reviewed in 2004). More recently, the DA D1 receptor has become a focus of
addiction research (Albertson et al., 1999; Ares-Santos et al. 2012; Chen et al., 2004; Moussa et
al., 2006; Vanderschuren et al., 1999).
The D1 receptors contribute to MA withdrawal, craving, relapse, and neurotoxicity.
Acute and chronic MA use selectively increases DA D1 receptors in the striatum (Worsley et al.,
2000) without altering the activity of basal adenylyl cyclase (Tong et al., 2003) or the
concentration of stimulatory striatal G protein (McLeman et al., 2008) when compared to agematched controls in post mortem analyses. Despite these findings, striatal DA D1 receptorstimulated adenylyl cyclase activity is decreased in acute and chronic MA users (Tong et al.,
2003). It is postulated that this effect is due to impaired coupling of D1 receptors with
stimulatory G proteins that then leads to a functional down-regulation in D1-stimulated adenylyl
cyclase activity and subsequent desensitization of striatal D1 receptors. This sequence of MAmediated events may be responsible for the symptoms of physiologic withdrawal and
consequential craving and relapse (Roberts-Lewis et al., 1986; Tong et al., 2003).
Pre-treatment with SCH-23390, a selective DA D1 antagonist, reduces mortality
following acute MA administration (Bronstein & Hong, 1995), and preserves both tyrosine
hydroxylase activity and [DA] in the striatum following chronic MA treatment in rats (Sonsalla
et al, 1986). These studies were among the first to attribute MA neurotoxicity, at least in part, to
DA D1 receptors. Methamphetamine-treated homozygous DA D1 receptor knockout mice have
diminished mortality and dopaminergic cell body loss within the basal ganglia as well as
preserved levels of tyrosine hydroxylase and DAT when compared to DA D1 receptor expressing
mice (Ares-Santos et al., 2012; Ito et al., 2008). Furthermore, DA D1 receptor knockout mice
offer more neuroprotection than their DA D2 receptor knockout counterparts (reviewed in Ares-
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Santos et al., 2013). Microscopic evaluation shows that DNA fragmentation and chromatin
condensation occur in immortalized CSM 14.1 neural cells and resembles an “apoptotic-like
process” following MA treatment (Cadet et al., 1997). Mechanistic studies in vitro and in vivo
indicate that MA-mediated postsynaptic apoptosis culminates from endoplasmic reticulum- and
mitochondria-dependent cascades (Jayanthi et al., 2004; Krasnova & Cadet, 2009) mediated, in
part, by D1 activation (Jayanthi et al., 2009).
These properties have made DA and activation of its receptors, specifically D1, the focus
of many studies aimed at understanding stimulant-induced neurotoxicity and diminishing the
phenomenon of withdrawal, craving, and relapse in humans (Karila et al., 2010; Tong et al.,
2003) and animal models (Shuto et al., 2006; Vanderschuren et al., 1999).
Methamphetamine-Induced Dopamine Release and (Nitro)oxidative Stress
Methamphetamine is one of the most potent psychostimulants as its half-life is 18-times
longer than and causes 3-times the amount of DA release as cocaine (Barr et al., 2006; Derlet et
al., 1990; Feldman et al., 1997;). In addition to DA receptor stimulation, the abundant release of
DA within the striatum is thought to be neurotoxic due in part to the generation of ROS (De Vito
& Wagner, 1989; O’Dell et al., 1991; Seiden et al., 1984). Dopamine has a greater ability to
form ROS and reactive metabolites than other catecholamines due to its higher rate of oxidation
and slower rate of cyclization. In both in vitro and in vivo models, DA is more cytotoxic when
directly injected into neuronal cells than other catecholamines (Graham, 1978; Rosenberg, 1988).
The ROS and subsequent toxicity are thought to result from DA autoxidation leading to the
hydroxyl radical (Giovanni et al., 1995), formation of dopaquinone (LaVoie & Hastings, 1999),
and, through redox-cycling of dopaquinone, the generation of the reactive superoxide radical
(O2•-; Stokes et al., 1999; see Figure 3).
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These neuropharmacological properties of MA-induced DA release may be the reason
that acute and chronic MA administration induces neuronal apoptosis, in contrast to cocaine that
does not initiate apoptotic pathways in the rat brain. It has been theorized that the antioxidant
capacity of the cell is sufficient to protect against cocaine-induced DA release, whereas the
magnitude of MA-induced DA release overwhelms the cellular defense mechanisms (Dietrich et
al., 2005; Mirecki et al., 2004). Methamphetamine neurotoxicity can be attenuated by
antioxidant supplementation (DeVito & Wagner, 1989; Wagner et al., 1985). It took several
years, however, before evidence of MA-induced intracellular pro-oxidant change was
documented. Yamamoto and Zhu (1998) were the first to show definitive evidence of prooxidant changes within the striatum by measuring malonyldialdehyde, a lipid peroxidation
product, in rats treated with MA (Yamamoto & Zhu, 1998). Since their initial report, additional
studies provide definitive evidence of pro-(nitro)oxidant protein changes in the striatum of
rodents consistent with increased RO/NS following MA administration (Gluck et al., 2001;
Imam et al., 2001). Subsequent research has been directed toward understanding and preventing
the sequelae of RO/NS-mediated neurotoxicity following MA treatment (Chen et al., 2004; Wu
et al., 2007).
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Figure 2: The Oxidation of Dopamine
In the initial step, dopamine (DA; A) can either be oxidized enzymatically by monoamine
oxidase A or B (MAO-A/B) or non-enzymatically by molecular oxygen (O2). In the former
process, enzymatic metabolism of DA produces the reactive hydroxyl radical (•OH) as a natural
by-product. In the latter mechanism, DA autoxidation results in production of the superoxide
radical (O2•−) and dopa-o-quinone (B). Dopa-o-quinone is then converted to a semi-quinone (C)
in the presence of NADPH. The quinone and semi-quinone, in the presence of O2 and NADPH,
redox-cycle between the reactive intermediates that generate a large quantity of O2•−. Superoxide
dismutase (SOD) converts O2•− to hydrogen peroxide (H2O2) in the presence of two hydrogen
ions (H+). Through the Fenton reaction, the H2O2 is converted to •OH. As shown, the oxidation
of DA is responsible for generation of great sums of highly reactive species.
Key Enzymes in Methamphetamine Neurotoxicity: Friend or Foe?
In addition to D1 receptor stimulation and ROS generation, the nitric oxide synthase and
superoxide dismutase isozymes (NOS, SOD) also play a key role in MA-induced apoptosis.
Nitric Oxide Synthase
There are three NOS isozymes generally referred to as neuronal (nNOS), endothelial
(eNOS), or inducible (iNOS). Both n- and eNOS are constitutively expressed and their activity is
Ca2+-sensitive, whereas iNOS expression must be induced and is Ca2+-insensitive. The Ca2+insensitive nature of iNOS is attributed to the tight coupling of calmodulin to iNOS at basal Ca2+
9

levels, while n- and eNOS require elevated levels of Ca2+ in order to bind and activate the
enzyme. The NOS isozymes catalyze the conversion of L-arginine, O2, and NADPH to NO•, Lor D/L-citrulline, and NADP. Inducible NOS operates as a high-output enzyme that continuously
produces NO• until it is degraded while n- and eNOS have variable, low-output activity
(Alderton et al., 2001). Several studies have reported a causative role for n- and iNOS
overstimulation in MA-induced neurotoxicity (Cadet et al., 2001; Di Monte et al., 1996; Imam et
al., 2001; Itzhak et al., 1996; 1998; 1999; Kita et al., 2003). Methamphetamine-induced striatal
toxicity is attenuated in mice that are co-administered 7-nitroindazole, a nNOS inhibitor (Di
Monte et al., 1996; Itzhak et al., 1996), or that lack the nNOS gene (Imam et al., 2001; Itzhak et
al., 1998). Methamphetamine administered to iNOS deficient mice also results in significantly
smaller depletions in striatal DA (Itzhak et al., 1999). A comparison of striatal DA concentration
in nNOS(-/-) mice and iNOS (-/-) mice following MA administration shows that both have
significantly less DA depletion, with nNOS(-/-) offering more protection (Itzhak et al., 2000).
Although studies clearly demonstrate protection from MA-induced neurotoxicity in animals with
diminished i- or nNOS expression and activity, there have been conflicting results regarding
which isozyme is the most neurotoxic; therefore, it has been difficult to identify the primary
target of intervention.
Superoxide Dismutase
Copper/zinc and manganese SOD are antioxidant enzymes found in the cytoplasm and
mitochondria, respectively, of cells (Cu/ZnSOD; MnSOD). These enzymes catalyze the
conversion of O2•-, a reactive oxidant and a byproduct of DA autoxidation, to the less reactive
hydrogen peroxide and O2 (St. Clair et al., 2002). Compromised SOD activity leads to an
increase in O2•- that can instantaneously react with NO• to produce peroxynitrite (ONOO-), a
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powerful RNS whose presence has been associated with tyrosine nitration, mitochondrial
dysfunction, and mitochondrial-mediated apoptosis (Squadrito & Pryor, 1998). Several studies
have reported the involvement of ONOO- in MA-induced apoptosis (Imam, et al., 2001).
Methamphetamine-treated mice overexpressing Cu/ZnSOD have reductions in the following:
striatal DA depletion (Cadet et al., 1994), ONOO- formation (Imam et al., 2001), and apoptosis
(Deng & Cadet, 2000). Likewise, MA treatment of transgenic mice that overexpress MnSOD
results in a significant decrease in striatal DA depletion, protein oxidation, and apoptosis
(Maragos et al., 2000). Studies using a known MnSOD inducer, deprenyl, demonstrated reduced
MA-induced neurotoxic effects in rats and SH-SY5Y neuroblastoma cells (Davidson et al, 2007).
However, some effects of deprenyl in these studies may be partially attributed to its inhibition of
monoamine oxidase, an enzyme that metabolizes DA. Although these studies implicate a
neuroprotective role for SOD isozymes in dopaminergic pathologies, no information is available
about their DA-mediated intracellular expression and activity.
AIM OF PRESENT STUDY
The goal of this work was to discover and identify intracellular processes that may be
responsible for the structural changes within the brain, such as regional gray matter
neurodegeneration (Thompson et al., 2004), striatal DA depletion, and DAT loss (Volkow et al.,
2001a); as well as functional impairments such as inattention and abnormal conflict adaptation
(Salo et al., 2007) that have been associated with MA abuse. We and others hypothesize these
losses are attributed to the cytotoxic effects of MA-induced DA release. If we can identify the
macromolecular changes and associated signaling pathways that are responsible for DA-induced
apoptosis, then appropriate interventions can be made to prevent further neurotoxicity. Since
there are no known effective treatments for MA-induced neurotoxicity or the long-term cognitive
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damage associated with MA use (Barr et al., 2006; Brackins et al., 2011), our goal was to
discover ways to attenuate MA-induced neuronal damage during the cycle of addiction. By
interfering with MA-mediated, DA-induced neurotoxicity we predict this will lessen the longterm behavioral and psychological consequences that foster further drug-seeking behavior and
relapse.
Notably the relevance of DA-specific postsynaptic RO/NS production, apoptosis, enzyme
expression, and signaling is not limited to MA neurotoxicity. The applicability of our findings
and this model also extends to other drugs of abuse and pathologies such as schizophrenia,
Parkinson’s Disease and Huntington’s disease, wherein DA toxicity is also fundamental to the
pathophysiology of those disease processes.
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CHAPTER 2
DOPAMINE STIMULATION RESULTS IN (NITRO)OXIDATIVE PROTEIN
CHANGES, MITOCHONDRIAL-MEDIATED APOPTOSIS, MNSOD NITRATION, AND
ACTIVATION OF MAPK AND AP-1 SIGNALING PATHWAYS IN AN IN VITRO
MODEL OF METHAMPHETAMINE NEUROTOXICITY
Introduction
Reactive oxygen and nitrogen species have long been implicated as mediators in MAinduced neurotoxicity (Cadet et al., 1997; DeVito & Wagner, 1989; O’Dell et al., 1991; Seiden
and Vosmer, 1984). Multiple studies have reported evidence of RO/NS in postsynaptic-models
of DA-induced neurotoxicity such as elevated nitrate levels and protection by antioxidant
supplementation with N-acetylcysteine or sodium metabisulfite (Chan et al., 2007; Chen et al.,
2003; 2004; Moussa et al., 2006); but these studies did not show if there were macromolecular
changes consequential to the (nitro)oxidative stress. It is necessary to determine if DA causes
pro-(nitro)oxidant protein alterations. Damaged membrane integrity by lipid peroxidation,
altered protein function by carbonyl formation, and diminished enzymatic activity by 3nitrotyrosine (3-NT) conjugation are all sequelae of oxidative and nitrosative stress that can
result in compromised cellular function. Identification of DA-mediated pro-(nitro)oxidant
changes, which is an aim of this study, will offer insight on the intracellular ramifications of the
previously reported spike in DA-induced RO/NS.
Given the RO/NS-plagued and neurotoxic nature of MA exposure, it is not surprising that
studies have reported MA administration triggers postsynaptic apoptosis (Cadet et al., 1997;
Cadet et al., 2001; Chang et al., 2007; Jayanthi et al., 2004; Krasnova & Cadet, 2009). To
differentiate the neurotoxicity imparted by MA-induced DA release from that attributed to MA,

13

several studies examined SK-N-MC cell viability following a range of 0-200 µM DA treatment
for 16-48 h. Reports showed decreased cell viability by the trypan blue exclusion test or 3-(4,5dimethylthiazol-2-yl)-2,5-dephenyl tetrazolium bromide (MTT) assay, but the studies did not
demonstrate whether this was an apoptotic or necrotic process (Chen et al., 2003; 2004; Moussa
et al., 2006). One study reported cleavage of effecter caspase 3 (CASP3) and poly(ADP-ribose)
polymerase (PARP) after 48 h of 50 µM DA treatment (Chan et al., 2007). Although cleavage of
these proteins suggest an apoptotic process, the markers are not specific for identifying
mitochondrial, endoplasmic, or receptor-mediated mechanisms (Li et al., 1997); and the time of
DA treatment far exceeded that used in most models (Chen et al., 2003; 2004; Junn &
Mouradian, 2001; Moussa et al., 2006; Zafar et al., 2006; Zhen et al., 1998). Since DA-induced
RO/NS is implicated in decreased cell viability and a majority of RO/NS are known to originate
in the mitochondria (Holley et al., 2010), we examined markers specific for mitochondrialmediated apoptosis following 0-50 µM DA for 24 h in the SK-N-MC cell line. Our research has
identified mechanisms through which DA-induced postsynaptic apoptosis occurs. This
information may be used to target susceptible subcellular organelles for intervention to prevent
or attenuate MA-mediated DA neurotoxicity.
Repeatedly, nitric oxide synthase isozymes have been reported as modulators of MAinduced neurotoxicity (Di Monte et al., 1996; Imam et al., 2001; Itzhak & Ali., 1996; Itzhak et
al., 1998; 1999). There are conflicting results as to which isozyme, when overexpressed, is the
most neurotoxic; therefore, it is difficult to identify a primary target of intervention. SK-N-MC
cells and primary rat striatal neurons had 150% greater iNOS expression and 200% increase in
iNOS activity than n- and e- NOS combined when treated with DA (Chen et al., 2003). This
data suggests a critical role for iNOS overexpression in DA-mediated neurotoxicity, but this
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study has not been replicated nor has the mechanism of DA-induced iNOS upregulation been
investigated in this model. It is hypothesized that glutamate-mediated NMDA calcium influx is
responsible for the activation of n- and e-NOS subsequent to MA exposure. In contrast, iNOS is
not calcium-sensitive nor is it constitutively expressed. Thus, little is known about its
mechanism of induction in MA/DA neurotoxicity. Given that 1) iNOS has the highest and
longest NO• output of the NOS isozymes, and 2) RO/NS such as NO• have been implicated in
MA/DA neurotoxicity, then it is critical to investigate the involvement and regulation of iNOS
following DA stimulation. This was a major goal in this study and reported in this chapter.
Overexpression of copper/zinc or manganese superoxide dismutase (Cu/ZnSOD,
MnSOD) isozymes attenuates pre- and postsynaptic MA-induced neurodegeneration in rodents
(Cadet et al., 1994; Maragos et al., 2000). Evidence suggests that overexpression of Cu/Zn- or
MnSOD prevents the cellular system from becoming overwhelmed with RO/NS species. It is
not known, however, if the cells attempt to mount an inherent, but insufficient, adaptive response
through upregulation of Cu/Zn or MnSOD following the MA-induced increase in DA
autoxidation and signaling. It is important to determine whether Cu/Zn- and/or MnSOD undergo
protein upregulation with a concurrent enhancement in enzymatic activity. This differentiation is
particularly important in MnSOD as this isozyme, unlike its cytoplasmic counterpart Cu/ZnSOD,
is essential for life and is susceptible to nitration by peroxynitrite with subsequent inactivation
(Li et al., 1995). If DA-stimulation does not induce SOD expression, then intervention of DA
neurotoxicity can be aimed at gene amplification. On the other hand, if MnSOD expression, but
not activity, is enhanced then the integrity of the enzyme must be investigated. If DA treatment
results in MnSOD nitration, then supplementation with general antioxidants may shift the
intracellular redox-balance in a manner that would permit the endogenous upregulation of
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MnSOD to exert its intended neuroprotective effect. In this study we assessed DA-mediated
MnSOD expression, activity, and nitration with a goal of understanding these processes and
directing our findings towards a protective intervention.
Despite the knowledge that NOS and SOD isozymes are associated with MA/DA
neurotoxicity, little is known about their signaling and regulation. We investigated two
transcription factors, Activator Protein-1 (AP-1) and Nuclear Factor kappa B (NFκB), which
have promoter sequences within human iNOS and MnSOD genes, are redox-sensitive, and
whose activation is induced by ROS-derived neuronal injury (Alderton et al., 2001; Flora et al.,
2002; Kiningham et al., 1997; 2001; Krasnova & Cadet, 2009; Pautz et al., 2010; St. Clair et al.,
2002). Methamphetamine injections enhance expression of transcription factors from the AP-1
family in mouse brain (Cadet et al., 2001; Krasnova & Cadet, 2009) and increase AP-1 DNA
binding in mouse striatum (Flora et al., 2002), but these studies did not investigate whether AP-1
activation is due to increased DA or another aspect of MA-mediated signaling. Similar to the
lack of data on AP-1 signaling, there are no studies in this model to investigate the possible
involvement of DA in NFκB activation either.
The members of the mitogen-activated protein kinase (MAPK) family, in particular junN-terminal kinase (JNK), have been cited as participants in MA-mediated signaling within the
striatum of rodents (reviewed in Krasnova & Cadet, 2009). Studies in postsynaptic
dopaminergic models yield conflicting results as to the identification of the MAPKs that are
specific to DA-stimulated signaling (Chen et al., 2004; Zhen et al., 1998). It is important to
differentiate which MAPKs are involved in DA-mediated signaling since each member of the
family has stereotyped modulatory functions such as those pertaining to cellular proliferation and
apoptosis, as well as upstream participants in AP-1 and NFκB activation. Identification of DA-
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stimulated signaling pathways would offer much insight into potential therapeutic targets, such
as modulation of: 1) enzyme expression, 2) apoptosis, and 3) adaptation.
In order to study the neurotoxic mechanisms of DA on postsynaptic neurons, we treated
human SK-N-MC neuroepithelioma cells with 0-50 µM DA and assessed for macromolecular
evidence of pro-(nitro)oxidative changes, markers of apoptosis, enzyme expression of SOD and
NOS isozymes, cellular adaptation, and activation of relevant cell signaling pathways including
JNK, MAPK p38, extracellular signal related kinases 1 and 2 (ERK1/2), AP-1, and NFκB. We
chose human SK-N-MC cells as our model for several reasons. The cells endogenously express
DA D1 receptors, and lack DAT as well as tyrosine hydroxylase activity (Chen et al., 2003;
Sidhu & Fishman, 1990). These properties are stereotypical of postsynaptic neurons and
distinguish them from their presynaptic counterparts. Unlike presynaptic neurons that undergo
terminal degeneration after MA exposure, postsynaptic neurons are susceptible to apoptosis
(Jayanthi et al., 2004; Zhu et al., 2006), which was a major focus of our study. The presence of
D1 receptors also enabled the study of DA-mediated signaling, while the absence of DAT and
tyrosine hydroxylase ensured that all pathophysiologic effects observed in this study were due to
an exogenous source of DA. The DA concentrations that were used mirror those found within
the human striatum after exposure to MA, and thus imparted physiological relevance to the study
(Feldman et al., 1997).
Our findings in this work provide information relevant to possible therapeutic options,
such as identification of specific enzymes that contribute to MA toxicity or, conversely, enzymes
with a protective function. By identifying these enzymes and understanding their regulation, it is
possible to either inhibit or upregulate their expression with the goal of averting MA-mediated,
DA-induced neurotoxicity.
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Materials and Methods
Cell culture and treatment paradigm
The human SK-N-MC neuroepithelioma cell line was obtained from the American Type
Culture Collection (Manassas, VA). These cells were maintained in RPMI 1640 medium
without phenol red and supplemented with 1% (v/v) nonessential amino acids, 1% antibiotics
(penicillin/streptomycin/neomycin; Invitrogen Corp.; Carlsbad, CA), 10% Nu-Serum (BD
Biosciences; San Jose, CA) and 1 mM sodium pyruvate and incubated at 37°C in a humidified
atmosphere with 5% CO2. All treatments were administered following 24 h pyruvate- and
serum-starvation, shielded from light, and accompanied by untreated or vehicle-treated control
samples (medium alone). Dopamine treatments were with 25 or 50 µM dopamine hydrochloride
(Sigma-Aldrich; St. Louis, MO) dissolved in medium. Although the concentration range of DA
used in these studies is higher than the normal human levels of 1-10 µM in the striatum, DA
content in pathological systems has been reported to reach as high as 50 µM (Chen et al., 2003;
Feldman et al., 1997). In the studies with polyethylene glycol superoxide dismutase (PEG-SOD;
Calbiochem; La Jolla, CA), the cells were pre-treated with 100 U PEG-SOD in transfectiongrade water for 30 min before administration of DA or control (medium alone). The cells were
microscopically visualized using a Nikon Diaphot Inverted phase microscope (Frank E. Fryer
Co., Cincinnati, OH) and photographed with a Nikon N2000 camera immediately prior to
collection.
Protein preparation and immunoblot analysis
For immunoblot analysis, SK-N-MC cells were plated at a density of 3 × 106/150 mm
dish then serum- and pyruvate-starved once cells were ~85% confluent. Following 24 h
treatment, mitochondrial fractions (for MnSOD nitration; Anantharaman et al., 2006)
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cytoplasmic samples (for CASP3 and CASP9), and whole-cell lysates (for all other samples)
were collected with the inclusion of protease inhibitors (pepstatin, leupeptin, aprotinin) at 1
µg/ml as previously described (Humphrey et al., 2005;). Protein concentrations were determined
by a colorimetric assay (Bio-Rad Laboratories; Richmond, CA) using bovine serum albumin as a
standard. Homogenate protein samples (100 µg/lane) were separated on 10, 12.5, or 15% SDSPAGE according to the method of Laemmli (1970) and transferred to a PVDF (3-NT) or
nitrocellulose membrane (all others). Transfer efficiency was assessed by staining with 0.1%
(w/v) Ponceau S. The membranes were washed with distilled water to remove excess stain and
then the nonspecific binding sites were blocked at room temperature for 1 h with Blotto (5%
[w/v] dried milk in tris-buffered saline with Tween-20 [TBS-T; 50 mM NaCl, 10 mM Tris-HCl
(pH 8.0), 0.05% (v/v) Tween-20]). The membranes were then incubated overnight at 4°C with
gentle shaking in Blotto and purified immunoglobulin for the protein of interest at 4°C with
gentle shaking. After three washes with TBST, the membranes were incubated with secondary
HRP-conjugated anti-rabbit or -mouse in Blotto for 1.5 h at room temperature with gentle
shaking. Following three washes with TBST and one with TBS the protein bands of interest were
visualized using the enchanced chemiluminescence detection system (Amersham Biosciences;
Little Chalfont, U.K.). To confirm equal protein loading, all blots except for i- and nNOS were
reprobed with a rabbit polyclonal anti- glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibody. Due to their high molecular weight, iNOS and nNOS blots were reprobed and
normalized with heat shock protein 70 antibody. Preliminary studies in our laboratory
determined there was no change in heat shock protein 70 expression upon treatment with 0-50
µM DA for 24 h. The dilutions and sources of each antibody used are as follows: n-, i-, and
eNOS (1:2500, 1:10,000, 1:1000; BD Transduction Laboratories; San Diego, CA); GAPDH
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(1:7500; Trevigen; Gaithersburg, MD), 4-hydroxy-2-nonenal (4-HNE; 1:1500; Alexis; San
Diego, CA); 3-NT (0.5 μg/mL; Upstate; Charlottesville, VA); CASP9 (1:1000), CASP3
(1:2500), cleaved CASP3 (1:1000), PARP (1:5000), MnSOD (1:4000), phosphorylated MAPK
p38 (1:750), phosphorylated ERK1/2 (1:3000), phosphorylated JNK (1:1000), heat shock protein
70 (hsp70; 1:3000; Cell signaling Technology; Beverly, MA), anti-rabbit and anti-mouse
secondary antibodies (1:3000; Santa Cruz Biotechnology; Santa Cruz, CA).
Transient Transfections and Luciferase Assay
Cells were plated at a density of 6.7 x 106/p100 plate and grown for 48 h. Using the
calcium phosphate method, the cells were transfected in Minimal Essential Medium
(supplemented with 10% heat inactivated fetal bovine serum, 1% nonessential amino acids, 1%
antibiotics [penicillin/streptomycin/neomycin], and 1 mM sodium pyruvate) with 6 μM of pGL2
vector (Promega; Madison, WI) with or without an AP-1 construct containing four known
consensus sequences (gift from Dr. Richard Niles, Marshall University), or pGL3 vector with or
without a NFκB construct (Panomics; Freemont, CA). After 7 h, the cells were washed twice
with PBS (137 mM NaCl, 3 mM KCl, 1 mM potassium phosphate, and 10 mM sodium
phosphate) and the medium was replaced with supplemented RPMI 1640 without phenol red.
The acclimated cells were plated in 24-well plates at a density of 3 x 105 cells/well and allowed
to acclimate for 24 h. The next day the cells underwent 24 h serum and pyruvate starvation, and
then were treated with 0-100 μM DA, 100 nM tumor necrosis factor (TNF), or 100 nM 12-Otetradecanoylphorbol-13-acetate (TPA; a phorbol ester) in serum- and pyruvate-free medium.
One, four, or six hours later the cells were lysed in 200 μL of reporter passive lysis buffer
(Promega) and frozen at -20°C overnight. Transcriptional activity was assessed using the
luciferase assay system (Promega) in a TD 20/20 luminometer (Turner Designs).
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(Mn)SOD Activity Assay
Superoxide dismutase activity was measured by the nitro blue tetrazolium-reduction
method as described (Anantharaman et al., 2006; and with the generous assistance of Dr.
Douglas Spitz, University of Iowa). Potassium cyanide (5 mM) was added to inhibit Cu/ZnSOD.
One unit of SOD activity was defined as the amount of SOD protein that caused a 50% reduction
in the background nitro blue tetrazolium-reduction rate. The change in MnSOD activity was
reported relative to the change in MnSOD protein expression for the same treatment.
Evaluation of MnSOD Nitration
The immunoprecipitation of 3-NT residues was performed as previously described
(Anantharaman et al., 2006). Briefly, isolated mitochondrial protein (200 µg) was resuspended
in 200 µL RIPA buffer. Anti-3-NT antibody (2 µg/mL) was added and incubated overnight at
4°C. Protein A/G agarose (20 µL) was then added to the mixture and incubated for 24 h.
Immunocomplexes were collected by centrifugation at 1000 x g for 5 min followed by 4 washes
with RIPA buffer. Immunoprecipitated samples were assessed for MnSOD protein expression by
western analysis as described above.
Data analysis
All experiments were replicated at least twice, and representative findings are shown.
Final statistical analyses were performed using Student’s t-test or three-way analyses of data and
variance (ANOVA) for multiple samples. Post hoc tests were examined with Tukey’s method
on SigmaStat software (SPSS Inc., Chicago, IL). A p value of <0.05 was considered statistically
significant.
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RESULTS
Markers of (nitro)oxidative stress are increased following dopamine exposure
Reports have indicated a role for RO/NS in DA-induced striatal cytotoxicity (O’Dell et
al., 1991; LaVoie & Hastings, 1999), and tyrosine nitration is a known finding in cellular
systems exposed to peroxynitire-generated RO/NS species (Squadrito & Pryor, 1998). A
western blot analysis (Figure 4) shows increased 3-NT residues in 25-50 µM DA-treated cells.
Furthermore, the amount of DA-mediated 3-NT appeared to be concentration-dependent.
Protein adducts, specifically 4-HNE adducts, have long been used as a marker of lipid
peroxidation (Spitz et al., 1990). To investigate the presence or absence of lipid peroxidation in
response to DA in our system, we treated SK-N-MC cells with 0-50 µM DA and evaluated 4HNE adducts through western analysis. Figure 5 shows 4-HNE adducted proteins in the 50 µM
DA samples at approximately 20-30 kDa that are not present in the control and 25 µM
treatments. Protein carbonyl formation is found in several disease states associated with
oxidative stress and is also used as a marker for ROS-induced protein alteration (Berlett &
Stadtman, 1997). We probed for protein carbonyl formation in samples treated with 0 or 50 µM
DA and found an elevation in the samples treated with DA compared to control (Figure 6). The
integrated findings from Figures 4-6 strongly suggest the presence of active RO/NS species
caused protein modifications typical of (nitro)oxidative stress following administration of DA.
Interestingly, the only modification noted at 25 µM DA was 3-NT, while all parameters
investigated showed alterations in 50 µM DA treated samples.
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Figure 3: Western Analysis of Dopamine-Induced 3-Nitrotyrosine (3-NT) Formation
Western analysis following 24-hour treatment with 0-50 µM DA. All bands to the left of the blot
represent molecular weight in kilodaltons. Treatment with 25-50 µM DA resulted in
concentration-dependent increase in 3-NT formation 3-NT. Figure is representative of findings
repeated at least twice.

Figure 4: Western Analysis of Dopamine-Mediated Adducted Proteins (4-HNE)
Western analysis following 24-hour treatment with 0-50 µM DA. All bands to the left of the blot
represent molecular weight in kilodaltons. Adducted proteins (4-HNE) were noted at 20-30 kDA
following treatment with 50, but not 25 µM DA. Figure is representative of findings repeated at
least twice.
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Figure 5: Western Analysis of Protein Carbonyl Formation After Dopamine Treatment
Western analysis following 24-hour treatment with 0-50 µM DA. All bands to the left of the blot
represent molecular weight in kilodaltons. Formation of protein carbonyl was observed
following treatment with 50 µM DA. Figure is representative of findings repeated at least twice.
Acute dopamine treatment resulted in mitochondrial-mediated cellular apoptosis
To determine if the observed DA-induced (nitro)oxidative stress resulted in activation of
an apoptotic pathway, SK-N-MC cells were treated with increasing concentrations of DA (0-50
µM) for 24 h and then assayed via western blot analysis for the presence of apoptotic markers.
Cleavage and thus activation of caspase 9 (CASP9) occurs specifically in mitochondrialmediated apoptosis immediately following apoptosome formation (Li et al., 1997). Examination
of the cleavage pattern of CASP9 in our model revealed a concentration-dependent decrease in
CASP9 proform following DA treatment with a parallel increase in its cleavage fragments
(Figure 7). Analysis of a downstream target of activated CASP9, effector CASP3, had the same
cleavage pattern as CASP9 following DA treatment with an increase in p17 and p19 CASP3
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cleavage products for 25-50 µM DA versus control (Figure 7). The nuclear enzyme PARP,
which functions in part to preserve DNA integrity and is thus considered an end-point for
apoptotic activation, is a substrate for cleavage by activated CASP3 (Oliver et al., 1998). Figure
7 shows concentration-dependent degradation in PARP at 116 kDa with a concurrent increase in
the 85 kDa PARP fragment following 25-50 µM DA treatment. The DA-induced cleavages of
CASP9, CASP3, and PARP suggest that cell death is occurring through activation of apoptotic
pathways that are, at least in part, mitochondrial-mediated.
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Figure 6: Immunoblot Analysis of Apoptotic Markers Following Dopamine Treatment
There is an increase in several apoptotic markers following 24 hours of treatment with 25 or 50
µM dopamine. Cleavage patterns of caspase 9 (CASP9, top figure), caspase 3 (CASP3, middle
figure) and poly(ADP-ribose) polymerase (PARP), bottom figure) suggest apoptosis occurred
after treatment with dopamine in a concentration-dependent manner. All bands to the left of the
blot represent weight in kilodaltons. All figure representations were repeated at least thrice.
Treatment with dopamine enhanced expression of the i- and n-NOS isozymes
Previous reports suggest that upregulation of the NOS isozymes may play a role in the
generation of RO/NS seen following treatment with DA (Chen et al., 2003). We examined the
expression of iNOS protein following 1, 6, 12, 16, and 24 h treatment with 0-50 µM DA. Figure
8 displays a time- and concentration-dependent increase in iNOS enzyme expression upon DA
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administration. Inducible NOS enzyme was not present at 1, 6, or 12 h (data not shown), but its
expression was noted at 16 and 24 h in cells treated with 25-50 µM DA (Figure 8). We also
investigated the n- and e-NOS isozymes for dopamine-enhanced expression. Although there was
a slight increase in nNOS expression after 25-50 µM DA at 24 h, it did not appear as marked as
the effect seen with iNOS (data not shown). We did not detect expression of eNOS in our model
at any time or DA concentration examined (data not shown).

Figure 7: Time- and Concentration-Dependent Protein Expression of iNOS Following
Dopamine Administration
Treatment with 25-50 µM DA resulted in a concentration- and time-dependent increase in iNOS
protein expression (below 140 kDa band, not shown) and normalized to heat shock protein 70
(HSP 70; at 70 kDa band, not shown). Figure is representative of findings repeated at least
twice.
Dopamine-mediated MnSOD nitration results in enzyme inactivation despite an increase in
enzyme levels
To determine if SK-N-MC cells underwent an adaptive response following the generation
of RO/NS, we measured MnSOD protein expression via western analysis following
administration of 0-50 µM DA. Figure 9 demonstrates a significant increase in MnSOD
expression for 50 µM treated samples vs. control (181%, p<0.0001) that is not seen with 25 µM
DA treatment. Despite the increase in MnSOD protein expression, there was not a concurrent
enhancement of enzymatic activity with DA administration (Figure 9). The discordant finding of
MnSOD protein versus activity suggests inactivation of the enzyme subsequent to its
upregulation.
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Figure 8: Immunoblot Analysis and Protein Activity of MnSOD in Response to Dopamine
Protein expression of MnSOD was significantly increased following 24 hours of dopamine
treatment at 50 µM (left figure), while MnSOD activity (right figure) was not concomitantly
elevated suggesting protein inactivation following upregulation. The data was normalized to
protein content and is expressed as mean ± S.E.M. of 5 independent experiments using Student’s
t-test. *p<0.0001 vs. control.
Since MnSOD is known to be inactivated by nitration of key tyrosine residues (Spitz et
al., 1990) and we have shown nitrotyrosine formation upon dopamine exposure (Figure 4), we
assessed the presence of MnSOD nitration in response to elevated RO/NS. Following overnight
immunoprecipitation of isolated mitochondria with 3-NT affinity sorbent, we detected elevated
levels of MnSOD by immunohistochemistry in the samples treated with 50 µM DA as shown in
Figure 10. Incorporating the data from Figures 9 and 10 suggests that inactivation of MnSOD,
secondary to nitration, negates a MnSOD-modulated adaptive response to the altered redox-state.
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Figure 9: Western Analysis of MnSOD Enzyme following Immunoprecipitation of 3Nitrotyrosine in Control versus Dopamine-Treated Samples
Following 24 h treatment with 0 or 50 µM DA, isolated mitochondria were immunoprecipitated
with 3-nitrotyrosine affinity sorbent followed by western analysis of MnSOD (immediately
below 19 kDa molecular weight marker). Dopamine treatment resulted in greater MnSOD
nitration than control. Figure is representative of findings repeated twice.
Supplementation with PEG-SOD attenuated markers of dopamine-induced cell death
In order to challenge the hindered activity of MnSOD post-DA exposure, we pre-treated
SK-N-MC cells for 1 h with 100 U PEG-SOD then treated with 0-50 µM DA. Treatment with
DA showed microscopic morphological changes such as membrane alterations as well as cellular
detachment and shrinkage that are consistent with toxicity (Figure 11C) and not visualized in
control treated cells (Figure 11A, vehicle only; Figure 11B, 100 U PEG-SOD only). Pretreatment with PEG-SOD followed by DA, however, yielded morphological characteristics more
consistent with control treated cells than DA only treated cells (Figure 11D); and thus appeared
protective against an apoptotic process. Parallel western analysis of DA-treated cells pre-treated
with PEG-SOD demonstrated a drastic decrease in PARP cleavage products as compared to DAonly treated cells (Figure 12) confirming the protective effect of PEG-SOD pre-treatment.
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Figure 10: Photographic Demonstration of Dopamine Toxicity and the Protective Effects
of Superoxide Dismutase in SK-N-MC Cells
SK-N-MC cells were pretreated for 30 min with vehicle (A, C) or 100 Units of pegylated
superoxide dismustase (SOD; B, D). The cells were then treated for 24 h with control (A, B) or
50 µM DA (C, D). Morphological analysis of the cells demonstrates cellular shrinkage and
detachment following dopamine treatment (C) that was precluded with superoxide pretreatment
(D).
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Figure 11: Parallel Western Analysis of Cleaved Poly(ADP-ribose) Polymerase Expression
with and without Dopamine and/or Superoxide Dismutase
Samples shown in Figure 11 were analyzed for Poly(ADP-ribose) Polymerase expression. In the
50 µM DA treated samples (C, D), pre-treatment with pegylated superoxide dismutase (SOD, D)
abolished dopamine-mediated PARP cleavage seen without SOD pretreatment (C). The results
indicate a protective role for exogenous antioxidants in this system of DA-induced toxicity.
Molecular weight markers on left of blot are in kDa and figure is representative of findings
repeated at least twice.
Dopamine increased AP-1, but not NFκB, reporter activity in the SK-N-MC cell line
To evaluate the potential role for DA-stimulated NFκB or AP-1 regulation, we transiently
transfected the cells with an NFκB, AP-1, or empty construct and examined luciferase activity.
Luciferase reporter activity in control or DA treated cells transfected with either an empty vector
or NFκB is shown in Figure 13. Although the positive control (100 nM TNF) significantly
increased reporter activity (p<0.005), treatment with as much as 100 µM DA failed to induce
NFκB transcription. Reporter activity for DA treated cells transfected with AP-1, however,
showed a significant increase in activity compared to control or DA-treated cells containing an
empty vector (P<0.005; Figure 14). Although a concentration-dependent significance of DAinduced AP-1 reporter activity was not reached, a trend was noted wherein higher [DA] resulted
in enhanced AP-1 luciferase activity.
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Figure 12: Luciferase Activity in NFκB-Transfected SK-N-MC Cells Treated with
Dopamine or Positive Control
Treatment with 100 nM tumor necrosis factor (TNF) yielded a significant increase in luciferase
signal indicating successful transfection of the NFκB construct. Dopamine administration,
however, did not enhance NFκB reporter activity suggesting that dopamine signaling does not
occur through the NFκB pathway in SK-N-MC cells. The data is expressed as mean ± S.E.M. of
5 independent experiments. *p<0.005 vs. control; # p<0.005 vs. empty vector.
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Figure 13: Luciferase Activity in Activator Protein-1-Transfected SK-N-MC Cells Treated
with Dopamine or Positive Control
Dopamine stimulation significantly increased AP-1 reporter activity compared to control and
dopamine-treated empty construct. There was no statistical difference in AP-1 transfected
luciferase activity among 25, 50, or 100 µM DA samples, and as such dopamine-stimulated AP-1
activity appears to be concentration independent. Treatment with 100 nM tissue plasminogen
activator (TPA) was used as a positive control. The data is expressed as mean ± S.E.M. of 5
independent experiments. *p<0.005 vs. control; # p<0.005 vs. empty vector.
Dopamine increased MAPK p38 and ERK1/2 phosphorylation
We evaluated the effect of DA on several pathways of MAPK phosphorylation. The
following MAPKs were examined after treatment with 0-50 µM DA for 1, 4, and 6 h: p38,
extracellular ERK1/2, and JNK. Phosphorylation of p38 (P-p38) was noted after 1 h treatment
with 50 µM DA. After 4 and 6 h, P-p38 was present within the 25 and 50 µM DA treated
samples with a notable time- and concentration-dependence. Phosphorylation of ERK1/2 (PERK1/2) was noted in control samples after 4 and 6 h and after 6 h treatment with 50 µM DA.
Unlike the other two MAPKs examined, phosphorylation of JNK was not observed at any of
concentration or time studied (data not shown). The findings implicate that phosphorylation of
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p38 and ERK1/2 follow DA stimulation; however, it is unlikely that JNK is involved in DAinduced signaling events.

Figure 14: Western Blot Analysis of Phosphorylated Protein Kinases p38 and ERK 1/2
with Variable Dopamine Treatment Time and Concentration
SK-N-MC cells were treated with 0, 25, 50 µM dopamine for 1, 4, or 6 hours then collected for
Western analysis. The top blot shows that phosphorylation of p38 is increased in a time- and
concentration-dependent manner following dopamine treatment. The bottom blot demonstrates
phosphorylation of ERK1/2 in all samples including control beginning at 4 hours, and markedly
increased after 6 h treatment with 50 µM dopamine. Molecular weight markers to the left of the
blot are in kDa and figures are representative of findings repeated at least twice.
DISCUSSION
The aim of this research was to study the effects of acute DA stimulation in
concentrations (25-50 µM) that mirror those found within the human striatum after exposure to
MA (Feldman et al., 1997). The properties of the SK-N-MC cell line make it an appropriate
model to study DA-induced postsynaptic striatal neurotoxicity and apoptosis, as opposed to
presynaptic terminal degeneration on which most studies have been previously focused.
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Our results show that acute DA-stimulation in the SK-N-MC cell line resulted in
increased nitrosative and oxidative stress with activation of the mitochondrial-mediated apoptotic
pathway. Although RO/NS have long been implicated as mediators in DA-induced neurotoxicity
(O’Dell et al., 1991; LaVoie & Hastings, 1999), we are the first to report DA-induced prooxidative/nitroxidative protein changes in the SK-N-MC model. We found concentrationdependent DA-induced 3-NT formation in response to 25 or 50 µM DA treatments (Figure 4).
Nitrotyrosine formation is seen in cellular systems exposed to RNS, in particular peroxynitritegenerated nitroxidative stress (Squadrito & Pryor, 1998). Previous studies have demonstrated
elevated levels of nitrite, a stable marker of NO•, following a 16 h treatment with 25-200 µM DA
in this cell line (Chen et al., 2003). This finding was replicated in two independent studies (Chen
et al., 2004; Moussa et al., 2006), and both of these studies proposed the presence of RNS
following DA treatment in SK-N-MC cells. Our results extend these findings by showing
structural changes in proteins that are consistent with (nitro)oxidative damage. Further, our
studies show evidence of RNS using lower physiological doses of DA, and not the toxicological
doses (≥100 µM DA) required to measure NO• in the Chen studies (Chen et al., 2003, 2004).
The studies by Moussa et al. reported a significant ~2.75 fold increase in nitrite levels compared
to control after 16 h treatment with 50 µM DA in SK-N-MC cells, which is contiguous with 3NT formation we reported at 24 h (Moussa et al., 2006). Although neither the Chen nor the
Moussa study assessed nitrite levels following 25 µM DA treatment, we suspect, based on our
findings, that nitrite levels are elevated.
Attenuation of DA-induced cytotoxicity by antioxidant supplementation or enzyme
overexpression has led many reports to infer a causal role for ROS and oxidative stress in
mediating cellular toxicity in SK-N-MC cells (Chan et al., 2007; Chen et al., 2003; Zafar et al.,
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2006). These studies suggested, but did not conclusively show, macromolecular evidence of
oxidative stress following DA stimulation. In our study, we are the first to show evidence of
extracellular DA-induced, pro-oxidant change. Four-hydroxy-nonenal adducted proteins were
observed following treatment with 50 µM DA in our system indicating the presence of lipid
peroxidation (Figure 5; Spitz et al., 1990). Adducts were noted at molecular weights of ~ 29 and
20 kDA. Similarly, 50 µM DA stimulation resulted in protein carbonyl formation and revealed
that DA-mediated protein oxidation had also occurred (Figure 6; Berlett & Stadtman, 1997). It is
interesting to note that in contrast to 3-NT formation which occurred at 25 and 50 µM DA
(Figure 4), 4-HNE and protein carbonyl formation (Figures 5 and 6) were only seen following
treatment with 50 µM DA under our experimental conditions. This finding suggests that RNS
are more prominent at lower DA concentrations than are ROS in this system. Another
explanation may rest on the ability of Cu/ZnSOD, MnSOD, glutathione peroxidase, and/or
catalase to effectively alleviate the ROS produced oxidative stress at 25 µM DA, while these
antioxidant systems may become overwhelmed at 50 µM DA. Given that: 1) elevated 3-NT is
seen at 25 µM DA and is suggestive of RNS, and 2) NO•, a RNS, is known to terminate
propagation of lipid peroxidation, then it is plausible that the NO• produced by 25 µM DA
stimulation diminished the extent of membrane damage sustained by lipid peroxidation and thus
4-HNE adducts were not observed. The ramp-up in RNS production might be an attempted
adaptive response in SK-N-MC cells exposed to DA. The expression of apoptotic markers
following 25-50 µM DA, however, does not support this theory.
We observed increases in CASP3, CASP9, and PARP cleavage following 24 h 25-50 µM
DA treatments (Figure 7). We are the first to report DA-mediated CASP9 cleavage in SK-N-MC
and thus show the apoptotic pathway is activated, at least in part, through the mitochondria (Li et
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al., 1997). A previous study with SK-N-MC reported 50 µM DA-induced CASP3 cleavage and
PARP fragmentation; however, the cells were treated for 48 h before they were collected and
assessed for CASP3 and PARP. The authors concluded that a minimum of 36 h treatment was
needed in order to observe diminished cell viability and elicit apoptotic signaling, even though
their data showed a significant decrease in MTT absorbance at 8, 12, and 24 h upon 50 µM DA
administration compared to control (Chan et al., 2007). The authors did not state if they
evaluated CASP3 and PARP cleavage at time-points prior to 48 h, therefore these changes
cannot be ruled out in this study.
Our results definitively demonstrated CASP-3, -9, and PARP cleavage at 24 h; therefore,
we propose pro-apoptotic signaling does occur within this time-frame of DA administration.
Consistent with our 24 h apoptotic findings, previous studies in SK-N-MC cells reported 16 h
treatment with 50 µM DA resulted in decreased cell viability (Chen et al., 2003; 2004; Moussa et
al., 2006). Although the loss of cell viability could be attributed to DA-induced necrosis,
findings such as mitochondrial cytochrome c release led the authors to suggest the mechanism of
cellular death was through an apoptotic pathway (Moussa et al., 2006). A study by Junn and
Mouradain in 2001, with SH-SY5Y cells, reported 15 h treatment with 200 µM DA resulted in
decreased cell viability by MTT assay, release of cytochrome c, and cleavage of CASP3,
CASP9, and PARP. In support of our findings, the report concluded DA treatment activated proapoptotic pathways. The concentration of DA used in their study, however, was four-fold
greater than the highest amount used in our study which questions the physiological relevance of
the findings. Furthermore, the presence of DAT in SH-SY5Y allows for DA uptake into the
cytoplasm of the cell and renders the cell susceptible to intracellular oxidative damage by DA.
The SK-N-MC cell line lacks DAT, thus only the effects of extracellular DA are observed. In
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addition, possession of DAT also renders the SH-SY5Y cell system a more appropriate model
for investigating pre-synaptic toxicity as opposed to post-synaptic toxicity toward which our
study is aimed.
Our report of DA-stimulated mitochondrial-mediated apoptosis is the first in this cellline. These findings offer insight into the mechanism by which DA-induces postsynaptic cell
death within the striatum. Mitochondrial- and endoplasmic reticulum-mediated postsynaptic
apoptotic-processes occur upon acute MA administration (Cadet et al., 1997; Jayanthi, et al.,
2005; Krasnova & Cadet, 2009). Our data suggests that the pathology of MA-induced apoptosis
may be the result of DA-activation of the mitochondrial pathway. Future studies in this model
should be aimed at the potential involvement of DA-activation of the endoplasmic reticulum
pathway, which would impart significance not only to MA neurotoxicity, but also that of
Parkinson’s and Huntington’s diseases, schizophrenia, and drugs of abuse other than MA.
In light of DA-induced RNS and subsequent apoptosis in our model, we evaluated the
presence of NOS isozymes and found a time- and concentration-dependent increase in iNOS
(Figure 8). There is a causative role of n- and iNOS overstimulation in MA-induced
neurotoxicity, but with much debate as to overexpression of which NOS isozyme is more toxic
(Cadet et al., 2001; Di Monte et al., 1996; Imam et al., 2001; Itzhak & Ali, 1996; Itzhak et al.,
1998; 1999; 2000; Kita et al., 2003). Our data is consistent with those that implicate the
inducible isozyme as the neurotoxic culprit in vivo (Itzhak et al., 1999) and in SK-N-MC cells
(Chen et al., 2003). One notable difference between our study and that of Chen et al. is the timedependence of DA-mediated iNOS expression. In the 2003 study, the authors show iNOS
protein expression after 1 h DA treatment whereas we did not observe iNOS until 16 h of
treatment. Without knowledge of the authors’ exact DA preparation protocol, it is hard to
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speculate why there is a large time difference in iNOS expression. One possibility is that the DA
used in their study was prepared with ascorbic acid or sodium metabisulfite, which is commonly
used in DA preparations to prevent DA oxidation. Preventing DA oxidation might render more
DA available for D1 receptor activation leading to quicker iNOS upregulation, since iNOS is
known to be predominately mediated through D1 in this system (Chen et al., 2003). Despite
differences in time until expression, both studies implicated iNOS as the principal expressed
isozyme following DA administration. The DA-stimulated overexpression of iNOS coupled
with its known high output of NO• suggests that iNOS is a mediator of DA-induced RNS, 3-NT
formation, and apoptosis in this model of postsynaptic neurotoxicity. Inducible NOS, therefore,
should be considered a target for neuroprotective intervention. Furthermore, iNOS has also been
named an important mediator of MA neurotoxicity in studies of MA-induced microglial
activation and microgliosis in animal models (LaVoie et al., 2004; Thomas et al., 2004) and
humans (Sekine et al., 2008). Understanding and modulating its overexpression in microglial
cells might prove neuroprotective and should be investigated in future studies.
We found an upregulation of the antioxidant enzyme MnSOD and demonstrated that SKN-MC cells attempted to mount an adaptive response to 50 µM DA (Figure 9). The absence of
MnSOD upregulation following 25 µM DA may be due to diminished ROS at that DA
concentration. Although there was 4-HNE and protein carbonyl formation in cells treated with
50 µM DA, there were no markers of ROS following treatment with 25 µM DA. Since oxidative
stress and ROS, namely O2•‾ and H2O2, are known to induce MnSOD expression (St. Clair,
2002); then it is plausible that the absence of ROS after 25 µM treatment precluded the
upregulation of MnSOD. Despite the significant enhancement of MnSOD protein upon 50 µM
DA treated cells, there was not a concomitant increase in enzyme activity (Figure 9). The
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discordant finding between protein vs activity points to alterations in MnSOD’s functional
integrity. Work by MacMillan-Crow et al. revealed that MnSOD was susceptible to tyrosine
nitration and dityrosine formation by peroxynitrite-mediated protein modifications. These
modifications resulted in MnSOD inactivation (MacMillan-Crow et al., 1998).
Tyrosine nitration and dityrosine formation are amino acid alterations that occur as a
consequence of nitroxidative and oxidative stress, respectively, and we have shown the presence
of both of these stressors in our DA treated cells. The 3-NT immunoprecipitants from 50 µM
DA treated cells contained a marked increase in MnSOD protein relative to control (Figure 10),
thus demonstrating that MnSOD was indeed nitrated by peroxynitrite in our system. We
hypothesize that DA-induced overexpression of iNOS markedly elevated NO• production, and
the NO• then instantaneously reacted with O2•‾ from the oxidation of DA to form peroxynitrite.
The peroxynitrite-compromised MnSOD function lead to even more O2•‾, which then increased
peroxynitrite production and furthered the inactivation of MnSOD. We speculate that the
continued production of peroxynitrite was responsible for the 50 µM DA-induced MnSOD
nitration (Figure 10) and lipid peroxidation (Figure 5) discovered in this system. Given that
MnSOD activity following 50 µM DA treatment was not reduced below that of control,
however, suggests that the enzyme maintained at least a basal level of activity (Figure 9). It is
unlikely that this finding is due to nitration of MnSOD protein away from the enzyme’s active
site as tyrosine modification of mutant MnSOD (Y34F; tyrosine → phenylalanine substitution of
the active site tyrosine residue most susceptible to nitration) by peroxynitrite still significantly
decreases MnSOD activity (MacMillan-Crow & Thompson, 1999). Peroxynitrite is required for
complete inhibition of MnSOD activity (MacMillan-Crow et al., 1998), thus it is expected that
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the 50 µM DA treated samples would have diminished the enzyme to zero activity. This
discrepancy in findings will be further investigated in future studies.
We hypothesized that the DA-mediated nitration and inactivation of MnSOD in this
system is of central importance based on findings from previous studies. Keller et al. and
Kiningham et al. reported overexpression of MnSOD protects against peroxynitrite production,
lipid peroxidation, PARP cleavage, and mitochondrial-mediated apoptosis in systems subject to
oxidative stress (Keller et al., 1998; Kiningham et al., 1999). Additionally, Maragos et al.
reported a reduction in MA-induced protein oxidation and striatal dopamine depletion in
transgenic mice that overexpress human MnSOD (Maragos et al., 2000). These studies suggest
that the DA-mediated inactivation of MnSOD in our system may be at least partly responsible
for the observed apoptosis.
To determine whether augmentation of SOD activity attenuated or even prevented DAmediated apoptosis in our cell system, we treated with 100 units PEG-SOD 30 min prior to 50
µM DA treatment. Our theory of inadequate SOD activity in SK-N-MC was substantiated by the
abolishment of DA-induced PARP fragmentation upon addition of PEG-SOD (Figure 12). The
microscopic morphological appearance of the SK-N-MC cells also suggests a protective effect
for PEG-SOD in the DA treated samples (Figure 11A-D). The presence of the polyethylene
glycol substituent of PEG-SOD permits SOD to diffuse inside of cells and act as an intracellular
antioxidant as opposed to solely an extracellular antioxidant that would be the case if the SOD
was not PEGylated. This distinction is important in examining the findings from Zafar et al. in
which pre-treatment with 1 mg/mL of SOD did not offer protection against DA-induced cell
death in SK-N-MC (Zafar et al., 2006). These results, however, can only be attributed to
extracellular actions of SOD on DA administration since the SOD was not PEGylated.
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Furthermore, the Zafar study used [DA] of 500 µM that far exceeds concentrations within the
striatum following MA use (Feldman et al., 1997). It is not surprising then that the supra-toxic
concentration of DA overwhelmed the antioxidant capacity of SOD.
Superoxide dismutase can also have differing levels of activity per mg of enzyme
rendering it imperative to standardize the use of an SOD mimetic by activity rather than amount
by weight (Squadrito & Pryor, 1998). The study by Zafar et al. used SOD measured in mg/mL
instead of units of activity; therefore, it is difficult to speculate the amount of active SOD that
was actually employed in that study. We standardized the amount of SOD activity in our studies
to 100 units and found it to be protective. Overall, the absence of 1) DA-triggered PARP
cleavage, and 2) morphologic changes consistent with cellular toxicity following pre-treatment
with PEG-SOD indicate that by improving the antioxidant capacity of the cellular system we can
prevent DA-stimulated apoptosis that is stereotypical of MA-induced neurotoxicity. The
importance of this finding is underscored by research that has reported the antioxidant capacity
of neural cells is sufficient to protect against cocaine-induced dopaminergic toxicity, whereas the
magnitude of DA release following MA (which is approximately four-fold higher) overwhelms
the cellular antioxidant defense mechanisms and thus leads to regional neurotoxicity (Dietrich et
al., 2005; Mirecki et al., 2004). Therefore, the antioxidant properties of MnSOD and its
susceptibility to inactivation via nitration make it a notable target for the prevention of MAtriggered DA neurotoxicity.
As stated earlier, identification of iNOS and/or MnSOD protein regulation is of
paramount importance to understand the modulation of MA-initiated DA neurotoxicity. To
elucidate possible regulators of iNOS or MnSOD expression, we assessed for DA-stimulated
reporter activity in SK-N-MC cells using NFκB or AP-1 constructs. Both of the aforementioned
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transcription factors: 1) are redox-sensitive, 2) have consensus sequences within the human
iNOS and MnSOD genes, 3) are upregulated following ROS-derived neuronal injury, and 4)
their regulation is responsive to MA treatment (Flora et al., 2002; Kiningham et al., 1997;
Krasnova & Cadet, 2009; Maragos et al., 2000).
We are the first to report that DA treatment of SK-N-MC does not enhance NFκB
reporter activity at 25, 50, or 100 µM DA (Figure 13), which is a concentration above the EC50 of
75 µM DA for the D1 receptor in this cell line (Moussa et al., 2006). In contrast, Chen et al.
(2003) reported that incubation with SN50, an NFκB inhibitor, significantly decreased nitrite
production following 16 h 50 µM DA treatment in SK-N-MC. Given the SN50-attenuationed
nitrite production along with previous reports of transcriptional regulation of iNOS by NFκB, the
authors concluded that DA-stimulated iNOS induction in SK-N-MC may occur in part through
NFκB regulation (Chen et al., 2003). Studies have questioned the selectivity of SN50 for NFκB
due to its inhibitory effects on several other transcription factors including AP-1, STAT (signal
transducer and activator of transcription; D’Acquisto & Ianaro, 2006; Torgerson et al., 1998),
and Nrf2 (nuclear factor E2-related factor; Theodore et al., 2008). Activator Protein-1 and
STAT have transcriptional binding sites within the human iNOS promoter, and Nrf2 has also
been shown to modulate iNOS expression (Rojo et al., 2010). The reported attenuation of nitrite
production following co-treatment with SN50 and DA, therefore, might have resulted from nonselective inhibition of a variety of transcription factors that are known to regulate iNOS
expression. A study by Flora et al. (2002) examined NFκB activation following acute MA
treatment. This study also reported an absence of MA-induced NFκB DNA binding in mouse
brain that was independent of exposure, time and brain region studied (Flora et al., 2002).
Combining the findings from our study with that of the Flora study, it is highly unlikely that
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MA-induced DA stimulation results in NFκB activation. Additional studies should be conducted
to solidify this data and perhaps remove NFκB as a potential target to upregulate MnSOD or
modulate iNOS overexpression in an attempt to prevent MA/DA-induced neurotoxicity.
We are the first to show dopamine-stimulated reporter activity in SK-N-MC cells
transfected with an AP-1 construct (Figure 14). We demonstrated that reporter activity tends to
increase proportionally with DA concentration. The findings in our model complements in vivo
reports that MA injections result in enhanced expression of transcription factors from the AP-1
family in mouse brain (Cadet et al., 2001) and increased AP-1 DNA binding in mouse striatum
(Flora et al., 2002). Additionally, given the non-selective nature of SN50, it is possible that the
reduced DA-triggered nitrite production reported by Chen et al. (2003) was a result of SN50
inhibition of AP-1 transcription and subsequent iNOS expression (Chen et al., 2003). Although
we have reported DA stimulation activates AP-1, we have not shown if its transcription
modulates iNOS or MnSOD expression as both enzymes contain consensus sequences for AP-1
within their promoter region. We also did not study if AP-1 activation was protective or
deleterious. Future studies will be aimed at employing transfection of dominant negative AP-1containing plasmid then assessing iNOS and MnSOD protein expression as well as PARP
fragmentation and cell viability. Once a definitive role for DA-stimulated AP-1 transcription is
determined, its activity can be modulated in a way to maximize cell survival.
The MAPK family is a known upstream modulator of AP-1. Given that DA stimulated
AP-1 activity in our model, we assessed the phosphorylation status of three members of the
MAPK family following DA treatment. Dopamine-stimulated p38 phosphorylation occurred in a
time- and concentration-dependent manner beginning at 4 h, while DA-stimulated ERK1/2
phosphorylation occurred after 6 h of treatment with 50 µM DA (Figure 15), and
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phosphorylation of JNK was not noted at any time or concentration of DA (data not shown).
Phosphorylated ERK1/2 also appeared in control treated samples at 4 and 6 h which is not
surprising as ERK1/2 activation is a well-documented response to serum-starvation within
animal and human cell lines (Jung et al., 1999). These findings implicate P-p38 and P-ERK1/2
as participants in DA-mediated cell signaling in SK-N-MC. Both of these MAPK members
mediate neuronal survival and death in response to various stimuli (Shaulian & Karin, 2001;
2002), thus their regulation in response to DA may be integral in modulating neurotoxicity or
neuroprotection.
Two previous studies in SK-N-MC cells yielded conflicting reports of DA receptormediated MAPK activation. The first study demonstrated a time- and concentration-dependent
increase in p38 and JNK phosphorylation following DA D1 receptor stimulation with a D1
selective agonist, SKF-38393. Phosphorylated p38 and P-JNK appeared with ~15 min with 1500 µM SKF-38393, while the presence of P-ERK1/2 was not detected after 120 min of
incubation with a maximum concentration of 500 µM SKF-38393 (Zhen et al., 1998).
Interestingly, the second study reported D1 stimulation with 200 µM SKF-38393 for 1 h resulted
in phosphorylation of ERK1/2 only, while 100 µM DA increased phosphorylation of ERK1/2
and p38, but not JNK (Chen et al., 2004). Although some of the data from the three studies on
MAPK activation in SK-N-MC are contradictory, there are findings that prove consistent. First,
p38 activation was shown in all studies, including ours. Second, in the two studies utilizing DA
as the stimulus, ERK1/2 was phosphorylated in both whereas the presence of P-JNK was slight
at best. The most striking difference came in the two studies that used a D1 agonist in which one
reported the phosphorylation of ERK1/2 while the other did not. In the context of deducing the
cause of MA-induced neurotoxicity, for which our study was designed, the MAPK regulation of
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DA stimulation is more relevant than that of specific D1 activation since DA, and not a nonoxidizable D1 agonist, is the endogenous neurotransmitter released after MA exposure. Thus the
roles of ERK1/2 and p38 should be further elucidated in DA-mediated pro-apoptotic vs
protective signaling as well as their potential downstream affect on AP-1. Future studies will
also investigate the role of the relatively new MAPK member, ERK5 (Zhou et al., 1995).
Reports indicate a protective role for ERK5 in cortical neurons (Liu et al., 2003) and in
dopaminergic cells exposed to 6-hydroxydopamine, an oxidative metabolite of DA (Cavanaugh
et al., 2006). Preliminary studies in our laboratory have shown phosphorylation of ERK5 in
response to DA treatment (data not shown), but its regulatory role in SK-N-MC has not yet been
investigated.
Taken together we have shown DA treatment resulted in protein modifications that are
consistent with (nitro)oxidative stress. We hypothesize that a central source of nitroxidative
stress is due to DA-triggered iNOS upregulation. The observed mitochondrial-mediated
apoptosis, we believe, resulted from nitration of and thus a failure to mount an adaptive response
by the key mitochondrial antioxidant enzyme, MnSOD. Dopamine did not stimulate NFκB
reporter activity but did significantly increase AP-1 luciferase signal. Furthermore, we identified
P-p38 and P-ERK1/2 as possible upstream modulators of DA-induced AP-1 activation. These
findings may be extended to not only MA neurotoxicity, but also several other pathologic
settings such as schizophrenia, Parkinson’s disease, Huntington’s disease, and various drugs of
abuse wherein dopaminergic neurotoxicity is fundamental. Interventions to augment antioxidant
capacity; up- or down-regulate MnSOD or iNOS, respectively; and target AP-1 activity and its
upstream modulation could prove to be neuroprotective in any of those disease processes.
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CHAPTER 3
THE MECHANISM BY WHICH DOPAMINE INDUCES MAPK P38 SERVES AS A
“MOLECULAR SWITCH” BETWEEN CELLULAR PROTECTION AND APOPTOSIS
IN A MODEL OF METHAMPHETAMINE NEUROTOXICITY
Introduction
With the growing world-wide popularity of methamphetamine and other stimulants of
abuse, much research has been dedicated to the study of their neurotoxic and addictive
properties. Despite the volume of research there is still a multitude of unanswered questions,
unexplored mechanisms, and a most unfortunate disconnect between basic and clinical research.
The goals of this research were to investigate mechanisms responsible for the profound
dopaminergic neurotoxicity associated with stimulant abuse and subsequently identify ways to
prevent this toxicity from occurring. Another focus of this work was to provide information on a
macromolecular and cellular level about potential neurotoxicity resulting from the use of
dopamine D1 receptor (D1) agonists and antagonists that are currently used in behaviormodifying studies of stimulant addiction.
Central to the pathology of addiction is the cyclic nature of the disease within the
mesolimbic and mesocortical pathways. The majority of acute neurotoxicity and initiation of the
addictive process occurs within the mesolimbic system, in particular the ventral and dorsal striata
(Chang et al., 2007; Goldstein et al., 2002; Veeneman et al., 2011; Volkow et al., 2004).
Dopamine has long been implicated as a mediator of this pathway by its ability to modulate
feelings of reward, motivation, and craving (Robinson and Berridge, 1993). The striatal toxicity
associated with stimulant abuse occurs as a result of the supra-physiologic DA concentration that
is reached following drug administration (O’Dell et al., 1991; 1993). These properties have
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made DA and activation of its receptors, specifically D1, the focus of many studies aimed at
understanding stimulant-induced neurotoxicity and diminishing the phenomenon of craving and
subsequent relapse in humans (Karila et al., 2010) and animal models (Shuto et al., 2006; van
Gaalen et al., 2006).
Many clinical and translational studies indicate a need for a mechanistic study of striatal
dopaminergic synapses (Goldstein et al., 2002; Veeneman et al., 2011; Volkow et al., 2004;),
especially the D1 expressing postsynaptic neurons (Chang et al., 2007; Krasnova & Cadet, 2009;
van Gaalen et al., 2006; Wang et al., 2012; Xu et al., 2005). The D1 postsynaptic striatal neurons
show sustained morphological changes as well as prolonged alterations in gene expression of the
Fos family following exposure to and absence from methamphetamine in rodent and human
striata (Badiani et al., 1999; Beauvais et al., 2010; Gross & Marshall, 2009; Robinson & Nestler,
2011). Their D2-expressing counterparts, however, revert to their original morphology after
cessation and only activate Fos in novel environments (Badiani et al., 1999; Lee et al., 2006).
The observed DA-mediated neurotoxicity and alterations in D1 postsynaptic striatal neurons are a
key factor in the development of addiction (Chang et al., 2007; Larson et al., 2010; Lee et al.,
2006; Robinson & Nestler, 2011). For these reasons, we studied and identified molecular
mechanisms and signaling systems responsible for DA-induced neurotoxicity in an in vitro
model of D1 expressing postsynaptic striatal neurons.
The SK-N-MC cell line was used as a model because they endogenously express the D1
receptor, are absent of dopamine transporters (DAT) and tyrosine hydroxylase and have a
morphology that is similar to postsynaptic medium-spiny density neurons of the striatum (Chen
et al., 2003; Sidhu & Fishman, 1990). To mimic dopaminergic neurotoxicity following stimulant
abuse, namely MA, we treated cells with 0-50 µM DA for 24 h to impart physiological relevance
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(Chen et al., 2003; Feldman et al., 1997) and subsequently monitored for indicators of cellular
toxicity. We also evaluated markers of apoptosis following treatment with a specific D1 agonist,
SKF-38393; and co-treatment with DA and a specific D1 antagonist, SCH-23390. Western
analysis of the cleavage products of caspase 3 (CASP3) and poly(ADP-ribose) polymerase
(PARP), as well as morphological changes consistent with cellular toxicity were used as
indicators of apoptosis (Cadet et al., 1997; Deng et al., 2002b; Lazebnik et al., 1994). In this
chapter, we demonstrated the involvement of mitogen activated protein kinase p38 (MAPK; p38)
and activator protein-1 (AP-1) following DA stimulation (Figures 13-15). In the current work,
we examined the pivotal role of p38 as orchestrator of cellular adaptation versus apoptosis
depending on D1 receptor stimulation or blockade. Recent evidence suggests the Fos family of
proteins function as modulators of stimulant-induced neurotoxicity, initiation of addiction, and
sustained morphologic changes following prolonged abstinence (Beauvais et al., 2010; Gross &
Marshall, 2009; Krasnova & Cadet, 2009; Larson et al., 2010; Martin et al., 2012; Robinson &
Nestler, 2011). We, therefore, studied the participation of cFos in DA-induced apoptosis and
AP-1 transcription.
In this study we describe multiple mechanisms of DA-induced cellular apoptosis in our
model including specific D1 activation as well as a D1-independent pathway. We are also the
first to report that MAPK p38 acts as a “molecular switch” between cellular adaptation and
apoptosis depending on the specific way it is activated by DA i.e., through D1 receptor
stimulation or through a D1-independent mechanism. Additionally, we show that cFos is a
regulator of DA-mediated AP-1 transcription and is pro-apoptotic. Furthermore, we provide
indirect evidence that DA-induced cFos activation occurs through a p38-dependent, D1 receptor
independent manner in our model of postsynaptic striatal neurons. Perhaps most compelling we
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have identified two ways to ameliorate DA-induced PARP fragmentation in this system by: 1)
co-inhibition of D1 and p38, or 2) inactivation of AP-1 through use of a cFos dominant negative.
The findings from this research are important to understanding several aspects of
dopaminergic neurotoxicity and addiction. This study offers mechanistic answers to clinical and
translational findings regarding stimulant-induced D1 postsynaptic striatal neurotoxicity,
including the identification of pro-apoptotic signaling pathways. The findings also demonstrate
a need for additional research to investigate potential neurotoxic side-effects in the use of D1
agonists to modify human behavior and cravings. Lastly, we identified two signaling molecules,
p38 and cFos, whose activation modulates the execution of DA-induced apoptosis and thereby
serve as potential pharmacological targets to avert stimulant neurotoxicity.
Materials and Methods
Cell culture and treatment paradigm
The human SK-N-MC neuroepithelioma cell line was obtained from the American Type
Culture Collection (Manassas, VA) and maintained in RPMI 1640 medium without phenol red
and supplemented with 1% (v/v) nonessential amino acids, 1% antibiotics
(penicillin/streptomycin/neomycin; Invitrogen Corp.; Carlsbad, CA), 10% Nu-Serum (BD
Biosciences; San Jose, CA) and 1 mM sodium pyruvate. Cells were incubated at 37°C in a
humidified atmosphere with 5% CO2. All treatments were 6 or 24 h and were administered
following 24 h pyruvate- and serum-starvation, shielded from light, and accompanied by
untreated and/or vehicle-treated control samples. Dopamine treatments were with 25 or 50 µM
dopamine hydrochloride (Sigma-Aldrich; St. Louis, MO) dissolved in cell culture medium. In
D1 dopamine receptor-specific studies, the cells were treated with 25 or 50 µM of the D1 specific
agonist, (R)-(+)-SKF-38393 (Sigma-Aldrich), in the absence of DA; or pretreated for 30 min
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with 10 µM of the D1 specific antagonist, (R)-(+)-SCH-23390 (Sigma-Aldrich), followed by cotreatment with DA as previously described (Chen et al., 2003; 2004). Both the D1 receptor
agonist and antagonist were dissolved in sterile water. In MAPK p38 inhibition studies, 2 µM of
the p38 selective inhibitor SB203580 (Calbiochem; La Jolla, CA) was administered 30 min prior
to treatment with SKF-38393, DA, or DA with SCH-23390. The concentration of SB 203580
was chosen based on the lowest concentration needed to return p38 phosphorylation found in
control cells. The SB 203580 was dissolved in 0.07% (v/v) DMSO. The cells were
microscopically visualized using a Nikon Diaphot instrument (Frank E. Fryer Co., Cincinnati,
OH) and photographed with a Nikon N2000 camera immediately prior to collection.
Protein preparation and immunoblot analysis
For immunoblot analysis, SK-N-MC cells were plated at a density of 3 × 106/150 mm
dish then serum-starved once cells were ~85% confluent. Following 24 h treatment, whole-cell
lysates were collected with the inclusion of protease inhibitors (pepstatin, leupeptin, aprotinin) at
1 µg/ml. Protein concentrations were determined by a colorimetric assay (Bio-Rad Laboratories;
Richmond, CA) using bovine serum albumin as a standard. Homogenate protein samples (100
µg/lane) were run on 10, 12.5, or 15% SDS-PAGE according to the method of Laemmli (1970)
and transferred to a nitrocellulose membrane. Transfer efficiency was assessed by staining with
0.1% (w/v) Ponceau S. The membranes were washed with distilled water to remove excess
stain, then the nonspecific binding sites were blocked at room temperature for 1 h with Blotto
(5% [w/v] dried milk in tris-buffered saline with Tween-20 [TBS-T; 50 mM NaCl, 10 mM TrisHCl (pH 8.0), 0.05% (v/v) Tween-20]). The membranes were then incubated overnight at 4 ̊C
with gentle shaking in Blotto with primary rabbit polyclonal antibodies directed against cleaved
caspase-3 (1:1000), phosphorylated p38 MAPK (1:750), phosphorylated heat shock protein 27
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(1:5000), or PARP (1:4500; Cell Signaling Technology, Inc; Beverly, MA.). After three washes
with TBST, the membranes were incubated with secondary HRP-conjugated anti-rabbit IgG in
Blotto (1:3000; Santa Cruz Biotechnology; Santa Cruz, CA) for 1.5 h at room temperature with
gentle shaking. Following three washes with TBST and one with TBS, the protein bands of
interest were visualized using the enhanced chemiluminescence detection system (Amersham
Biosciences; Little Chalfont, U.K.). To confirm equal protein loading, all blots were reprobed
with a rabbit polyclonal anti-GAPDH antibody (1:50,000; Trevigen; Gaithersburg, MD).
Transient transfection and reporter assay
Cells were plated at a density of 4.2 × 106/100 mm plate and grown for 48 h (~75%
confluent). One hour prior to transfection, the cells were washed twice with phosphate-buffered
saline (PBS; 137 mM sodium chloride, 3 mM potassium chloride, 1 mM potassium phosphate,
10 mM sodium phosphate) and then the medium was replaced with Minimal Essential Medium
supplemented with 10% heat inactivated fetal bovine serum (Invitrogen Corp.), 1% nonessential
amino acids, 1% antibiotics, and 1 mM sodium pyruvate. The cells were then transfected with 6
μM of a pGL2 vector (Promega; Madison, WI) with or without the AP-1 construct (a generous
gift from Dr. Richard Niles, Marshall University School of Medicine) via the calcium phosphate
method (Graham & van der Eb, 1973). The AP-1 construct contains four consensus binding
sequences inserted into a pGL2 vector. In the dominant negative assays, 0.75 μg of CMV-500
vector with or without an A-Fos construct (a generous gift from Dr. Charles Vinson, National
Institutes of Health) was co-transfected with an empty or AP-1 containing pGL2 vector. The AFos construct is a dominant negative to c-Fos and works by adding an amphipathic, acidic
extension to the N-terminus of the Fos leucine zipper thereby inhibiting DNA binding of AP-1 in
equimolar competition (Olive et al., 1997). After 7 h incubation in transfection medium, the
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cells were washed twice with PBS and the transfection medium was replaced with the regular
culture medium. The next day, the cells were trypsinized and plated in 24-well plates at a
density of 3.0 × 105 cells/well for the reporter assay or at 4 × 106 cells/100 mm plate for
immunoblot analysis and allowed to grow overnight. Following 24 h serum and pyruvate
starvation, the cells were treated for 6 or 24 h for reporter or immunoblot analysis, respectively,
with 0-50 µM DA or 100 nM TPA; the latter compound is a strong inducer of AP-1
transcriptional activity and was used as a positive control. The cells were lysed in 200 μL of
reporter passive lysis buffer (Promega) then frozen at -20°C overnight. Transcriptional activity
was assessed using the luciferase assay system (Promega) in a TD 20/20 luminometer (Turner
Designs; Sunnyvale, CA).
Data analysis
All experiments were at least twice replicated (for n ≥ 3) and representative findings are
shown. Grubbs’ Outlier Test was performed on all data, and significant data outliers were
removed from further analysis. Final statistical analysis was conducted using three-way analyses
of data and variance for multiple samples. Post hoc tests were examined with Student NewmanKeuls on SigmaStat software (SPSS Inc., Chicago, IL). A p value of <0.05 was considered
statistically significant.
Results
D1 receptor stimulation via SKF-38393 exacerbates PARP cleavage in a manner
independent of CASP3
We have previously shown that acute DA treatment led to apoptosis in this cell model
(Figure 7). To study the involvement of D1 receptor stimulation in the activation of apoptotic
pathways, we treated SK-N-MC cells with 0-50 µM of DA or the specific D1 agonist, SKF-
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38393, for 24 h. We analyzed caspase 3 (CASP3) and poly (ADP-ribose) polymerase (PARP)
cleavage products to serve as indicators of apoptosis. Effector CASP3 was cleaved following
DA treatment (Figure 16) with a significant increase in the levels of p17 and p19 products in
cells treated with 25 (p<0.05) and 50 (p<0.01) µM DA versus control. The dopamine-induced
cleavage was concentration dependent. SKF-38393 did not significantly increase CASP3
cleavage compared to control suggesting that DA-mediated CASP3 cleavage occurs through a
pathway independent of D1 activation (Figure 16).
Figure 17 demonstrates that treatment with 25 or 50 µM DA significantly decreased
native PARP levels in a concentration dependent manner (p<0.001 vs control). Treatment with
50 µM DA resulted in a ~36% greater loss of full-length PARP when compared to 25 µM DA
(p<0.05). This change was accompanied by a significant elevation in PARP fragmentation in 25
and 50 µM DA treated cells when compared to control (p<0.05, p<0.005; Figure 17). Following
treatment with 25 and 50 µM SKF-38393 there was a significant decrease in full-length PARP
protein (p<0.001; Figure 17) with a concomitant significant increase in its fragmented products
(p<0.001; Figure 17) vs control. Further analysis of 25 µM SKF-38393 treated cells
demonstrated a significant increase of ~23% in PARP cleavage compared to 25 µM DA
treatment (p<0.05) with the same trend observed between the 50 µM DA treated groups. The
observed PARP fragmentation suggests that D1-mediated apoptosis occurred, albeit through a
mechanism that circumvented CASP3 cleavage.
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Figure 15: Qualitative and Quantitative Protein Analysis of Caspase 3 Cleavage in
Dopamine or SKF-38393 Treated SK-N-MC
Treatment with dopamine for 24 hours resulted in concentration-dependent caspase 3 cleavage
(CASP3) whereas D1 stimulation with the D1 agonist, SKF-38393, did not. The findings suggest
that dopamine-induced caspase 3 cleavage occurs through a process that is independent of the D1
receptor. The data was normalized to protein content and is expressed as mean ± S.E.M. of 6
independent experiments. *p<0.05, **p<0.001 vs. control; # p<0.05 between concentrations of
same treatment.
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Figure 16: Qualitative and Quantitative Protein Expression of Full-Length and Cleaved
Poly(ADP-ribose) Polymerase Following Dopamine or SKF-38393 Treatment
Treatment with 25-50 µM dopamine or the D1 agonist, SKF-38393, for 24 hours resulted in a
significant decrease in full-length PARP with a concurrent increase in PARP fragmentation.
Dopamine treatment decreased the presence of full-length PARP in a concentration dependent
manner, suggesting more toxicity at higher dopamine concentrations. Treatment with 25 µM
SKF-38393 yielded more PARP cleavage than the same concentration of dopamine, while there
was no difference between the 50 µM treated SKF-38393 or dopamine treated groups. The data
was normalized to protein content and is expressed as mean ± S.E.M. of 5 independent
experiments. *p<0.05, **p<0.001 vs. control; # p<0.05 between concentrations of same
treatment; + p<0.05 between treatments of the same concentration.
D1 receptor antagonist SCH-23390 has no significant effect on CASP3 cleavage, but
attenuates DA-induced PARP fragmentation
Dopamine is known to rapidly autoxidize and, thus, it accordingly acts as a strong
oxidizing agent that causes neuronal cytotoxicity (Chan et al., 2007; Krasnova & Cadet, 2009).
In order to study the oxidative effects of DA on SK-N-MC cells and determine if the differences
noted between 25 and 50 µM DA could be attributed to non-D1 receptor mediated apoptotic
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mechanisms, we pre-treated the cells with 10 µM SCH-23390, a specific D1 antagonist, then
assayed CASP3 and PARP cleavage patterns following a 24 h treatment with 0-50 µM DA. The
data in Figure 18 illustrate that pre-treatment of the 25 µM DA group with 10 µM SCH-23390
attenuated the significant increase in CASP3 cleavage that was seen with DA treatment when
compared to control. The effect of D1 receptor blockade at 50 µM DA revealed a different
pattern of CASP3 cleavage where addition of SCH-23390 resulted in a significant increase in
fragmentation when compared to control (p<0.001) but not significantly different than DA alone.
The results from Figure 18 suggest CASP3 cleavage occurred, at least in part, through a non-D1mediated mechanism.
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Figure 17: Qualitative and Quantitative Protein Expression of Cleaved Caspase 3
following Dopamine Treatment with and without Blockade of the D1 receptor with SCH23390
Pre-treatment with 10 µM SCH-23390, a D1 antagonist, prior to 24 h treatment with 25-50 µM
DA did not significantly attenuate CASP3 cleavage compared to DA vehicle (sterile water)
treatment alone. The data was normalized to protein content and is expressed as mean ± S.E.M.
of 3 independent experiments. **p<0.001 vs. control; # p<0.05 between concentrations of same
treatment.
As shown in Figure 19, the PARP cleavage pattern of 25 µM DA samples were like those
of CASP3 (Figure 18). Pre-treatment of 25 µM DA samples with SCH-23390 decreased PARP
fragmentation by ~30% when compared to 25 µM DA but did not reach statistical significance.
In contrast to cleaved CASP3, a significant decrease in PARP fragmentation was observed in the
SCH 23390 pre-treated 50 µM DA group when compared to DA alone (~41% reduction; p<0.05)
suggesting D1 antagonism is protective against 50 µM DA-mediated PARP cleavage (Figure 19).
Although SCH-23390 offered protection when compared to DA alone, D1 antagonism did not
prevent PARP fragmentation as there was a significant elevation in both DA groups when
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compared to control (p<0.05) suggesting that DA oxidation triggers the activation of proapoptotic pathways.

Figure 18: Pre-Treatment with D1 Antagonist Attenuates Dopamine-Mediated PARP
Cleavage
Pre-treatment with 10 µM SCH-23390, a D1 antagonist, prior to 24 h treatment with 50 µM DA
significantly attenuated PARP cleavage compared to DA vehicle treatment alone. SCH-23390
pre-treatment, however, did protect against significant PARP fragmentation when compared to
control. The data was normalized to protein content and is expressed as mean ± S.E.M. of 4
independent experiments. *p<0.05 vs. control; $ p<0.05 vs. vehicle (sterile water).
Dopamine or SKF-38393 treatment results in MAPK p38 phosphorylation
In order to ascertain if the intracellular signaling molecule mitogen activated protein
kinase (MAPK) p38 was involved in either the DA-mediated, CASP3-dependent apoptotic
pathway; or through the D1-specific, CASP3-independent mechanism, we analyzed p38
phosphorylation after a 24 h treatment with 0-50 µM DA or SKF-38393. Figure 20 shows that
all treatments significantly increased phosphorylation when compared to control indicating that
p38 is activated in response to D1 stimulation (p<0.001 for 50 µM DA, p<0.01 for 25-50 µM
SKF, p<0.01 for 25 µM SKF-38393). A concentration-dependent trend in phosphorylation was
59

observed in the DA and SKF-38393 groups. To ascertain if there was D1-independent activation
of MAPK; p38, the cells were pre-treated with 10 µM SCH-23390 followed by 25-50 µM DA.
Receptor antagonism did not result in a significant change in p38 phosphorylation compared to
DA alone (data not shown) suggesting MAPK p38 is also activated through a D1-independent
pathway.

Figure 19: Both Dopamine and D1 Agonist Increase p38 Phosphorylation
MAPK p38 phosphorylation (P-p38) was significantly increased 24 h after treatment with 25-50
µM DA or the D1 agonist, SKF-38393 as measured by Western Blot analysis. The data was
normalized to protein content and is expressed as mean ± S.E.M. of 4 independent experiments.
* p<0.01, ** p<0.001 vs. control.
Inhibition of MAPK p38 with SB203580 attenuates toxicity in 25 µM DA treated
cells, but enhances toxicity with 50 µM DA or SKF-38393 treatment
To decipher whether the observed p38 activation was protective or deleterious, we pretreated cells with 2 µM of the cell-permeable p38 inhibitor, SB203580, then analyzed CASP3
and PARP cleavage. Preliminary studies were conducted using a range of SB203580
concentrations (0, 1, 1.5, 2, and 5 µM) prior to treatment with 50 µM DA then assessing MAPK
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p38 phosphorylation via western analysis (data not shown). Pre-treatment with 2 µM SB203580
was chosen for all subsequent experiments as that concentration provided ~63% (± 4%, n=3)
reduction in phosphorylation following 50 µM DA administration, and thus returned MAPK p38
phosphorylation status to that of control. Furthermore, p38 inhibition was verified via western
analysis following each experiment that involved SB203580. Figure 21 shows that SB203580
pre-treatment resulted in a significant increase in CASP3 cleavage when compared to control for
50 µM DA (p<0.05), 25 µM SKF-38393 (p<0.005) or 50 µM SKF-38393 (p<0.001), but not 25
µM DA. The inhibition of p38 phosphorylation significantly exacerbated CASP3 cleavage for
both SKF-38393 treated samples when compared to samples in which p38 underwent
phosphorylation (p<0.001). In contrast, inhibition of p38 phosphorylation afforded significant
protection against CASP3 cleavage in the 25 µM DA group (p<0.05). The inhibition of p38
phosphorylation also resulted in a concentration-dependent cleavage of CASP3 within the SKF38393 treated groups, which was not present without the inhibitor (p<0.05). Although
concentration-dependence was seen within the DA treated samples without p38 inhibition, the
dependence was enhanced following administration of SB203580 (p<0.001). Unlike the results
in Figure 18 where DA resulted in greater CASP3 cleavage than treatment with the D1 agonist at
the same concentration, the addition of SB203580 reversed this finding. Following p38
inhibition, treatment with the D1 agonist resulted in greater cleavage than DA alone at the same
concentration. A greater effect of inhibition of p38 phosphorylation was observed among with
25 µM relative to 50 µM DA although both were significant (2.8 vs 1.4-fold; p<0.001 and
p<0.005). Results from Figure 21 suggest that inhibition of p38 phosphorylation augments
CASP3 cleavage in a manner associated with increased D1 receptor activation, as demonstrated
by elevated cleavage following D1 stimulation with SKF-38393 and 50 µM DA. Conversely,
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p38 inhibition stabilized CASP3 after 25 µM DA concentration and thus presumably less D1
activation occurred.

Figure 20: Qualitative and Quantitative Protein Expression of Caspase 3 Cleavage
following Inhibition of p38 Phosphorylation in Samples Treated with D1 Agonist or
Dopamine
Inhibition of p38 phosphorylation with SB203580 significantly enhanced CASP3 cleavage in
samples treated with the D1 agonist, SKF-38393, when compared to SKF-39393 treatment alone.
Conversely, p38 inhibition prior to 25 µM DA treatment attenuated CASP3 cleavage compared
to DA alone and returned the levels to that seen in control. The data was normalized to protein
content and is expressed as mean ± S.E.M. of 6 independent experiments. *p<0.05, **p<0.001
vs. control; $ p<0.05, $$ p<0.001 vs. vehicle; # p<0.05, ## p<0.001 between concentrations of
same treatment; ++ p<0.001 between treatments of same concentration.
Figure 22 shows inhibition of MAPK p38 phosphorylation resulted in a significant
decrease in native PARP when compared to control for all groups indicating cellular toxicity was
present (p<0.001). In the 25 µM DA treated samples, however, inhibition of p38
phosphorylation resulted in a significant stabilization of native PARP when compared to 25 µM
DA without p38 inhibition (p<0.001). An opposite trend was observed in the 50 µM DA and 2562

50 µM SKF-38393 treated cellular samples whereupon p38 inhibition led to decreased levels of
native PARP protein. The effect was significant in the 50 µM SKF-38393 treatment group with
a 70% reduction in full-length PARP following p38 inhibition compared to 50 µM SKF-38393
alone (p<0.05). As seen with Figure 21, the addition of SB203580 resulted in more toxicity as
evidenced by less native PARP protein in samples treated with the D1 agonist compared to DA of
the same concentration. The effect was significant in the 25 µM samples with an 80% more
reduction in native PARP levels following SKF treatment compared to DA treated cells
(p<0.01). When the phosphorylation of p38 was inhibited, DA treated cells had a significant
concentration-dependent loss of native PARP. The 50 µM DA treatment resulted in 58% less
native PARP than 25 µM (p<0.001). Investigating the DA- or SKF-38393-induced cleavage
pattern of PARP following SB 203580 pre-treatment revealed complementary findings to those
of native PARP where inhibition of p38 hampered PARP cleavage in 25 µM DA while
augmenting it in SKF-38393 and 50 µM DA treated samples (data not shown).
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Figure 21: Qualitative and Quantitative Protein Expression of Full-Length PARP
following Inhibition of p38 Phosphorylation in Samples Treated with D1 Agonist or
Dopamine
Inhibition of p38 phosphorylation with SB203580 led to significant decreases in full-length (Pro)
PARP upon 24 h treatment with the D1 agonist, SKF-38393, suggesting a protective function of
p38 in its phosphorylated form when stimulated by the D1 agonist. Significant stabilization of
PARP was noted upon p38 inhibition in samples treated with 25 µM DA, suggesting a
deleterious effect from p38 activation. The data was normalized to protein content and is
expressed as mean ± S.E.M. of 5 independent experiments. **p<0.001 vs. control; $ p<0.05, $$
p<0.001 vs. vehicle; # p<0.01, ## p<0.001 between concentrations of same treatment; ++
p<0.001 between treatments of same concentration.
The findings from Figures 21 and 22 suggest a critical role for p38 acting as a molecular
buffer against the toxicity triggered by increased DA concentration and isolated receptor
stimulation with SKF. At 25 µM DA, MAPK p38 seems to have a different role as a proapoptotic modulator.
To confirm cytotoxicity and substantiate the findings in Figures 21 and 22, we
administered the same treatment regime as above, then microscopically examined SK-N-MC
cells to assess morphological changes consistent with toxicity as previously described (Herdman
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et al., 2006; Figures 23F-J). Figure 23 shows control (A), 25 (B), and 50 (C) µM DA, as well as
25 (D) and 50 (E) µM SKF-38393 treated SK-N-MC cells. All treatments (Figure 23 B-E)
displayed morphologies consistent with toxicity such as membrane alterations, cell shrinkage,
and cell detachment when compared to control treated cells. The morphological changes
following pre-treatment with SB 203580 are consistent with the data in Figures 21 and 22 in that
p38 inhibition of 25 µM DA treated cells (Figure 23G) showed protection against cytotoxicity
when compared to 25 µM DA alone (Figure 23B). Conversely, p38 inhibition prior to 50 µM
DA (Figure 23H) and 25-50 µM SKF-38393 (Figures 23I-J) treatment displayed morphological
characteristics consistent with exacerbated toxicity compared to 50 µM DA or SKF-38393 alone.
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(A)Vehicle Control

(F) 0 DA, + SB203580

(B) 25 µM DA

(G) 25 µM DA, + SB203580

(C) 50 µM DA

(H) 50 µM DA, + SB204580
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(D) 25 µM SKF-38393

(I) 25 µM SKF-38393, + SB203580

(E) 50 µM SKF-38393

(J) 50 µM SKF-38393, + SB203580

Figure 22 A-J: Parallel Examination of SK-N-MC to Assess Morphological Changes
Consistent with Toxicity Following Dopamine or D1 Agonist Treatment with and without
Inhibition of p38 Phosphorylation
SK-N-MC cells were pretreated for 30 min with vehicle A-E or 2 µM SB203580, a p38
inhibitor, F-J. The cells were then treated for 24 h with the following: A and F) control; B and
G) 25 µM DA; C and H) 50 µM DA; D and I) 25 µM SKF-38393; E and J) 50 µM SKF-38393.
Morphological analysis of the cells shows that pre-treatment with SB203580 is protective in 25
µM DA treated samples (B, G); while it exacerbates toxicity in 25 (D, I) and 50 (E, J) µM SKF
treated samples. Interestingly, inhibition of p38 phosphorylation with SB203580 yielded little
morphological change in cells treated with 50 µM DA (C, H).
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Antagonism of D1 coupled with MAPK p38 inhibition completely abolishes DAinduced toxicity
Given that SCH-23390 and SB203580 each affected CASP3 stabilization when
administered prior to 25 µM DA, we co-incubated the cells with both the D1 antagonist and the
p38 inhibitor. This treatment regime was done to gauge if the CASP3 protection afforded by
SCH-23390 or SB203580 was working through a similar or different mechanistic pathway. Coincubation completely abrogated CASP3 cleavage in 25 µM DA treated samples returning the
levels of cleavage to that of control (Figure 24). The 25 µM DA samples co-treated with SCH23390 and SB 203580 were also significantly protected against cleavage when compared to
SCH-23390 or SB203580 treatment alone (p<0.05, p<0.01).
Unlike the 25 µM DA treated group, pre-treatment of 50 µM DA samples with SCH23390 resulted in a different CASP3 cleavage pattern than SB203580. D1 antagonism provided
slight protection against cleavage following 50 µM DA treatment, while p38 inhibition
significantly intensified fragmentation (p<0.01). Co-incubation of 50 µM DA treated cells with
SCH-23390 and SB203580, however, prevented CASP3 cleavage that was seen following DA
alone, returning the level of cleavage to that of control (p<0.001; Figure 24). Examining the
differences between co-incubation of 50 µM DA samples and individual pre-treatment revealed
significant decreases in cleavage when compared to either SCH-23390 or SB 203580 alone
(p<0.001).
As was seen with CASP3 cleavage, co-incubation with SCH-23390 and SB203580
effectively nullified PARP fragmentation in the 25 and 50 µM DA samples when compared to
DA treatment alone and returned levels to that of control (Figure 25; p<0.01, p<0.001).
Correspondingly, samples co-treated with SCH-23390 and SB203580 significantly attenuated
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PARP fragmentation when compared to either pre-treatment with SCH-23390 (p<0.05) or SB
203580 alone (p<0.05 for 25 µM DA, p<0.001 for 50 µM DA). The results in Figure 25 indicate
that D1 antagonism attenuates, but does not prevent, PARP-mediated apoptosis thus indicating
that D1 stimulation and DA autoxidation are both mechanisms of toxicity in this cell line. When
coupled with D1 blockade, p38 inhibition abolishes PARP fragmentation revealing a deleterious
role for MAPK p38 activation when activated through a D1 independent mechanism.

Figure 23: Co-Incubation with p38 Inhibitor and D1 Antagonist Prior to Dopamine
Demonstrates Decreased Caspase 3 Cleavage Compared to Dopamine Alone
Co-incubation (dark-gray bars) with a p38 inhibitor, SB203580 (light-gray bars), and D1
antagonist, SCH-23390 (white bars) 30 min prior to 25-50 µM DA administration prevented
CASP3 cleavage that was seen in DA alone (black bars). Likewise, co-incubation with
SB203580 and SCH-23390 resulted in significantly less CASP3 cleavage than pre-treatment
with SB203580 or SCH-23390 alone. The data was normalized to protein content and is
expressed as mean ± S.E.M. of 3 independent experiments. *p<0.05, **p<0.001 vs. control; $
p<0.01, $$ p<0.001 vs. vehicle; # p<0.05, ## p<0.001 between concentrations of same treatment;
+ p<0.05; ++ p<0.001 between treatments of same concentration.
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Figure 24: Co-Incubation with p38 Inhibitor and D1 Antagonist Prior to Dopamine
Demonstrates Decreased Caspase 3 Cleavage Compared to Dopamine Alone
Co-incubation (dark-gray bars) with a p38 inhibitor, SB203580 (light-gray bars), and D1
antagonist, SCH-23390 (white bars) 30 min prior to 25-50 µM DA administration prevented
PARP fragmentation that was seen in DA alone (black bars). Likewise, co-incubation with
SB203580 and SCH-23390 resulted in significantly less PARP fragmentation than pre-treatment
with SB203580 or SCH-23390 alone. The data was normalized to protein content and is
expressed as mean ± S.E.M. of 3 independent experiments. *p<0.05, **p<0.001 vs. control; $
p<0.01, $$ p<0.001 vs. vehicle; # p<0.05, ## p<0.001 between concentrations of same treatment;
+ p<0.05; ++ p<0.001 between treatments of same concentration.
D1 receptor stimulation enhances HSP27 expression in a manner attenuated by
MAPK p38 inactivation
To further study the mechanism of the D1-mediated, MAPK p38-dependent antiapoptotic pathway, as well as the D1-independent, p38-dependent pro-apoptotic pathway, we
investigated heat shock protein 27 (HSP27). This protein is a downstream target of p38 and has
neuroprotective properties such as CASP3 stabilization when upregulated or phosphorylated
(Bruey et al., 2000; Pandey et al., 2000). Treatment with 50 µM DA or 25-50 µM SKF-38393
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led to a significant increase in HSP27 protein compared to control (Figure 26; p< 0.01, p< 0.05,
p<0.05, respectively). A significant concentration-dependent elevation in HSP27 occurred
between 25 and 50 µM DA (p<0.005) that was nullified by pre-treatment with SB203580.
Moreover, inhibition of p38 resulted in significantly reduced HSP27 protein in all samples with
the largest decrease reported in the 50 µM SKF-38393 group (~80% ; p<0.05 for 25 µM DA,
p<0.001 for 50 µM DA, p<0.01 for 25 µM SKF-38393, p<0.001 for 50 µM SKF-38393). The
data suggests that HSP27 protein expression is positively associated with D1 receptor simulation
and is dependent on p38 activation.

Figure 25: Enhanced Phosphorylation of Heat Shock Protein 70 Following Dopamine or
D1 Agonist Appears Dependent Upon p38 Activation
Phosphorylation of HSP27 was significantly elevated following 24 h treatment with 50 µM DA
or 25-50 µM SKF-38393, a D1 agonist. Inhibition of p38 with SB203580 significantly decreased
HSP27 phosphorylation in all treatments. The results suggest HSP27 phosphorylation is p38dependent. The data was normalized to protein content and is expressed as mean ± S.E.M. of 3
independent experiments. *p<0.05, **p<0.01 vs. control; $ p<0.05, $$ p<0.01, $$$ p<0.001 vs.
vehicle; ## p<0.005 between concentrations of same treatment.
Dopamine induces AP-1 transcriptional activity through a MAPK p38-dependent,
D1-independent mechanism
To further study the dual role of dopamine-induced MAPK p38 activation, we
investigated a known downstream target of p38-mediated signaling, Activator Protein-1 (AP-1).
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This regulatory protein is a redox-sensitive transcription factor whose activation is known to
have pro-apoptotic as well as proliferative properties (Sun and Oberley, 1996; Shaulian & Karin,
2002). Figure 27 shows that transient transfection with an AP-1 construct resulted in a
significant increase in luciferase reporter activity following 6 h of 50 µM DA treatment of the
transfected cells when compared to control (p<0.001) or 50 µM DA-treated cells transfected with
the empty pGL2 vector (p<0.05). Pre-treatment of the transfected cells with 1.5 µM SB203580
followed by 50 µM DA significantly decreased reporter activity when compared to DA alone
(p<0.05), and did not significantly increase reporter activity when compared to control or DA
treatment of cells containing the empty vector (Figure 27). This data indicates that AP-1
transcription is upregulated following DA treatment in the SK-N-MC cell line in a manner
dependent upon activation of p38.

Figure 26: Dopamine-Induced AP-1 Activity Appears to be Mediated Through p38
AP-1 reporter activity (gray bars) was significantly increased 6 h after treatment with 50 µM
DA. Pre-treatment with 1.5 µM SB203580 significantly decreased AP-1 luciferase activity. The
results suggest DA-induced AP-1 activity is mediated through p38. The data is expressed as
mean ± S.E.M. of 3 independent experiments. **p<0.001 vs. control; $ p<0.05 vs. empty vector;
# p<0.05 vs. 50 µM DA.
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To decipher whether receptor stimulation or autoxidation was responsible for AP-1
activation, we treated AP-1 or PGL2 (empty vector) transfected cells with 0-100 µM of DA or
SKF-38393, or pre-treated cells with 10 µM SCH-23390 followed by 50 µM DA. The cells were
also treated with a phorbol ester (TPA, 100 nM) to serve as a positive control for AP-1
activation. Figure 28A illustrates that 25-100 µM DA-, but not in 25-100 µM SKF-38393-,
induced significant increases in AP-1 reporter activity when compared to control or the empty
vector (p<0.001; p<0.001). Furthermore, there was a significant increase in reporter activity
among DA treated samples when compared to cells receiving the same concentration of SKF38393 (p<0.005) suggesting that AP-1 activity is not regulated through D1. Pre-treatment with
the D1 antagonist, SCH-23390, followed by 50 µM DA (Figure 28B) revealed a significant
increase in AP-1 activity when compared to control or DA-treated empty vector (p<0.05). SCH23390 pretreatment did not hinder reporter activity when compared to 50 µM DA alone
indicating that AP-1 activation is sensitive to DA stimulation through a non-D1-mediated
mechanism. The results from Figures 28A and 28B suggest that AP-1 activation occurs in a D1independent, perhaps redox-sensitive manner in SK-N-MC.
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Figure 27 A, B: AP-1 Reporter Activity is Enhanced by D1 Antagonism but Not D1 Agonist
(A) AP-1 reporter activity (gray bars) was significantly increased 6 h after treatment with 25-100
µM DA compared to control or DA-treated empty vector, whereas treatment with 25-100 µM
SKF-38393, a D1 agonist, did not enhance reporter activity in AP-1 transfected cells. (B) Pretreatment with 10 µM SCH-23390, a D1 antagonist, did not significantly attenuate DA-induced
AP-1 luciferase activity when compared to DA alone. The results suggest DA-induced AP-1
activity is mediated through a D1-independent mechanism. The data is expressed as mean ±
S.E.M. of 4 independent experiments. *p<0.05, **p<0.005 vs. control; $ p<0.05, $$ p<0.005 vs.
empty vector; ## p<0.005 between treatments of the same concentration.
Dopamine-stimulated AP-1 transcription occurs through a cFos-containing complex
and is a mediator of DA-induced apoptosis
The AP-1 complex exists as a homo- or hetero-dimer of proteins from the subfamilies of:
Jun, Fos, Jun dimerization partners, activating transcription factors, and Maf. The most
transcriptionally active and stable dimer is a cJun:cFos heterodimer, and cFos is a known
substrate for MAPK p38 phosphorylation (Halazonetis et al., 1988; Shaulian & Karin, 2002). In
order to determine if cFos was a constituent of the DA-sensitive AP-1 complex in SK-N-MC, we
transiently co-transfected cells with an empty pGL2 or AP-1 vector and 0.75 µg of an empty
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CMV-500 vector or a vector containing a dominant negative to cFos, designated as A-Fos. We
then treated with 0-50 µM DA or 100 nM TPA and measured AP-1 reporter activity (Figure
29A). Treatment with 50 µM DA in the AP-1, CMV-500 co-transfected cells potentiated
reporter activity over 3-fold when compared to control or empty vector (p<0.001). Dopaminetreated cells co-transfected with AP-1 and A-Fos had significantly reduced reporter activity
(~45% reduction) when compared to AP-1 and CMV-500 co-transfected cells (p<0.001) and did
not yield a significant increase when compared to control or empty vector (Figure 29A).
Treatment with TPA in the AP-1, A-Fos co-transfected cells significantly reduced reporter
activity by ~66% when compared to AP-1 transfected cells (p<0.05) and thereby confirmed
effectiveness of the A-Fos dominant negative vector. The data in Figure 29A indicate that DAinduced AP-1 transcriptional activity occurs in part through activation of cFos.
Activator protein-1 stimulation is involved in the induction of both pro- and antiapoptotic mechanisms in the nervous system (Krasnova & Cadet, 2009; Shaulian & Karin,
2002). To determine if DA-induced, c-Fos mediated AP-1 activation was protective or
deleterious in our model, we transiently transfected the dominant negative A-Fos or empty vector
into SK-N-MC cells then treated with 0-50 µM DA. After 24 h DA treatment, we assessed
PARP fragmentation via immunoblot analysis. A parallel co-transfection with AP-1, A-Fos or
empty vectors was conducted to measure luciferase activity following 6 h DA treatment to
ensure that AP-1 transcription was successfully attenuated by A-Fos at the DNA level. Figure
29B shows that transfection with A-Fos substantially diminished PARP cleavage when
compared to control or empty vector. Our observation that A-Fos attenuated DA-induced PARP
fragmentation is the first to report that c-Fos-dependent AP-1 activation is a mediator of
apoptosis following DA treatment in the SK-N-MC cell line.
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Figure 28 A, B: Co-Transfection with a Dominant Negative to cFos, A-Fos, Precludes
Dopamine-Induced PARP Cleavage
(A) Dopamine-induced AP-1 reporter activity (gray bars) was significantly decreased when cotransfected with a dominant negative to cFos, A-Fos (white bars). Co-transfection with A-Fos
significantly attenuated TPA-induced AP-1 activity 6 h after treatment thereby confirming
efficacy of A-Fos. (B) Western analysis of A-Fos transfected cells showed attenuation of PARP
fragmentation (Cl. PARP) following treatment with 25-50 µM DA for 24 h. The findings
suggest that AP-1 is a mediator in dopamine-induced apoptosis through a mechanism involving
PARP fragmentation. The data is expressed as mean ± S.E.M. of 3 independent experiments.
*p<0.05, **p<0.001 vs. control; $ p<0.05, $$ p<0.001 vs. empty vector; # p<0.05, ## p<0.001
between AP-1/CMV-500 transfected cells of the same treatment.
Discussion
In the present study we identified two mechanisms through which DA treatment
stimulated apoptosis in a model of D1-expressing postsynaptic striatal neurons. Elegant research
from a multitude of clinical and translational studies has identified stimulant-induced cell death
in D1 expressing postsynaptic neurons (Chang et al., 2007; Krasnova & Cadet, 2009). Studies
have detailed mechanisms responsible for stimulant- and DA-induced toxicity, but a majority of
these studies have been aimed at striatal presynaptic terminal degeneration (Jayanthi et al., 2004;
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Krasnova & Cadet, 2009). Limited knowledge on the mechanisms responsible for postsynaptic
cell death, however, may create a potential barrier to further research on stimulant-induced
neurotoxicity.
In addition to DA receptor stimulation, the structural properties of DA render a fraction
of the neurotransmitter susceptible to oxidation prior to receptor interaction (Giovanni et al.,
1995; Stokes et al., 1999). By employing the specific D1-agonist SKF-38393 or -antagonist
SCH-23390, we studied the toxicity of D1 stimulation versus non-receptor mediated DA effects
in our model of postsynaptic striatal neurons. Figure 17 demonstrates alterations in PARP
consistent with apoptosis following treatment with 25-50 µM SKF-38393. The data from Figure
17 indicated D1 stimulation was sufficient to induce apoptosis. Poly (ADP-ribose) polymerase
cleavage tended to be greater in samples treated with D1 agonist than those receiving equivalent
concentrations of DA (Figure 17). The immediate implications of this finding are clear in that 1)
D1 stimulation is a mechanism of DA toxicity by apoptosis, and 2) caution should be taken when
using D1 agonists to thwart craving and relapse in addiction research. Our results are congruent
with previous studies in SK-N-MC that reported 16 h treatment with 50 µM SKF-38393 resulted
in decreased cell survival as measured by the trypan blue exclusion test (Chen et al., 2003) or
MTT assay (Moussa et al., 2006). Although these studies reported decreased cell survival
following D1 stimulation, they did not demonstrate the mechanism by which this occurred nor
identified the process as apoptotic or necrotic. The novelty in our findings comes from further
investigation of the mechanism by which D1 stimulation causes apoptosis in SK-N-MC. The
cleavage of effector caspase 3 prior to PARP fragmentation is a prominent event of apoptosis
(Herceg and Wang, 1999; Lazebnik et al., 1994). Caspase 3 cleavage occurs following
activation of the Fas ligand/Fas death receptor as well as mitochondrial- and endoplasmic-
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mediated apoptosis from a variety of stimuli (Breckenridge et al., 2003) including MA (Jayanthi
et al., 2004; 2005). We are the first to report that in our model, however, D1-mediated PARP
cleavage occurred through a process that circumvented CASP3 cleavage (Figure 16). Apoptosisinducing factor (AIF) is a caspase-independent facilitator of apoptosis that is released in response
to mitochondrial membrane damage (Susin et al., 1999; 2000), and its presence has been
documented in neuronal (Cregan et al., 2002) as well as SK-N-MC apoptotic processes (Komjáti
et al., 2004). We hypothesize that D1 stimulation with 25-50 µM SKF-38393 resulted in
mitochondrial damage that facilitated the release of AIF and subsequent apoptosis. We
previously presented indirect evidence of mitochondrial stress in SK-N-MC following DA
treatment, such as caspase 9 cleavage (Figure 7) as well as nitration and inactivation of MnSOD
(Figures 9 and 10). There are limited and conflicting results about the involvement of stimulantinduced AIF in neuronal apoptosis. One study reported translocation of AIF from the
mitochondria to cytoplasmic fractions in mouse striata ≤ 7 days following a single treatment with
40 mg/kg MA (Jayanthi et al., 2004). A later study using primary rat neurons isolated from the
frontal cortex reported no change in AIF location or amount following 24 h incubation with 1-2
mM amphetamine or 1-3 mM cocaine (Cunha-Oliveira et al., 2006). The discrepancies between
the two studies could be attributed to disparity in the brain region from where the samples were
acquired, or due to the difference in stimulants used in the study. Our study design more closely
mimics that used by Jayanthi et al. wherein the authors concluded AIF was a participant in MAinduced striatal apoptosis (Jayanthi et al., 2004). Future work should be aimed at identifying the
possible role of AIF following D1 stimulation in SK-N-MC.
Pre-treatment with 10 µM of the D1 specific antagonist, SCH-23390, significantly
decreased PARP cleavage when compared to 50 µM DA treatment alone but did not afford
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complete protection from PARP fragmentation (Figure 19). The findings in Figure 19 indicate
that although D1 receptor blockade attenuated DA-induced apoptosis, a non-D1 mediated process
also facilitated cell death following 25-50 µM DA treatment. Accordingly, two previous studies
reported preserved cell viability upon pre-treatment of SK-N-MC with 10 µM SCH-23390 when
compared to 16 h treatment with 50 µM DA alone; however, there was still a significant decrease
in viability in cells pre-treated with SCH-23390 when compared to control treated cells. These
studies concluded that DA cytotoxicity occurred through a D1-dependent route as well as an
oxidative pathway that was independent of D1 stimulation (Chen et al., 2003; Moussa et al.,
2006). Examination of CASP3 cleavage (Figure 18) following SCH-23390 pretreatment was
equivalent to that seen in 50 µM DA alone thereby suggesting the apoptotic protection afforded
by D1 receptor blockade occurred through a process independent of CASP3 stabilization.
Relating these findings to those in Figures 16 and 17 again implicate AIF as a possible
participant specific to D1 stimulation. It is plausible that D1 blockade by SCH-23390 hinders
AIF-mediated apoptosis and, thus, significant preservation of PARP is seen (Figure 19).
Attenuation of MA-induced striatal neurotoxicity has also been reported in mice (Xu et al., 2005)
and rats (Jayanthi et al., 2005) following pre-treatment with SCH-23390. Both studies
demonstrated complete protection against MA-induced presynaptic toxicity with only partial
attenuation of postsynaptic apoptosis, which the latter is congruent with our findings. Jayanthi et
al. noted SCH-23390 pre-treatment blocked postsynaptic Fas expression but only partially
suppressed CASP3 activation. The authors reported SCH-23390 inhibited MA-induced
hyperthermia and suggested that this may explain the non-caspase 3 mediated protection from
striatal apoptosis (Jayanthi et al., 2005). We observed the same finding in regards to CASP3 and
apoptosis in our model; however, the system we employed removed the element of
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hyperthermia-induced toxicity. We propose AIF and other intracellular signaling pathways may
be responsible for D1-dependent, CASP3-independent MA-induced striatal apoptosis. To our
knowledge there is a lack of research in any model on D1-mediated activation of AIF. Further
studies should be aimed at identifying the plausible participation of AIF in D1-mediated versus
D1-independent mechanisms of DA-induced apoptosis in this cell line.
In an effort to examine cell signaling involved in DA-mediated apoptosis, we studied the
effects of D1- vs. non-D1-mediated activation of MAPK p38. This signaling molecule is known
to regulate both apoptosis and adaptation in response to various stimuli (Shi et al., 2011).
Additionally, we previously demonstrated that DA-induced p38 phosphorylation in SK-N-MC
cells (Figure 15). Figure 20 shows p38 was phosphorylated following treatment with the D1
agonist SKF-39393, while pre-treatment with the D1 antagonist SCH-23390 did not significantly
decrease p38 phosphorylation when compared to DA alone (results not shown). These results
suggest p38 is phosphorylated by D1-dependent and DA-mediated D1-independent pathways.
The latter mechanism may occur as a result of an alteration in intracellular redox status following
DA autoxidation. Previous studies have incongruent findings regarding D1-mediated p38
phosphorylation in SK-N-MC. One study revealed p38 phosphorylation following 5-120 minute
treatment with 1-500 µM SKF-38393 in a manner that was insensitive to pre-treatment with 10
µM of the D1 antagonist SCH-23390 (Zhen et al., 1998). Another study reported an absence of
p38 phosphorylation upon treatment with 10-200 µM SKF-38393 for 1 h despite significant p38
activation following treatment with 50-100 µM DA (Chen et al., 2004). In the latter experiment,
however, the absence of a loading control may explain the discrepant findings between the two
studies. We are the first to report that p38 is phosphorylated through both D1-dependent and
DA-mediated non-D1-dependent mechanisms in SK-N-MC.
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The significance of p38 phosphorylation following D1-dependent or D1-independent DA
stimulation became evident in our system after inhibition of the MAPK by pre-treatment with
SB203580. As shown in Figure 22, p38 inactivation prior to D1 stimulation with SKF-38393
significantly decreased parental PARP protein levels when compared to samples without p38
inhibition. This finding suggests an adaptive response was initiated following D1-dependent p38
activation. Of interest, p38 inactivation was significantly protective at the level of parental
PARP in samples treated with 25 µM DA, while SB203580 pre-treatment was inconsequential at
the level of PARP in samples treated with 50 µM DA. Contrary to the protective role of p38
following isolated D1 stimulation, p38 activation following treatment with 25 µM DA appeared
to be pro-apoptotic. The discordant consequences of p38 phosphorylation suggest that its
downstream targets and/or activity may differ depending on the original signaling stimuli.
The results from Figure 25 show that p38 inactivation is protective at the level of PARP
fragmentation following 25-50 µM DA stimulation in a D1-independent manner. The complete
attenuation of PARP fragmentation following p38 inhibition suggests that p38 signaling is proapoptotic when activated through a D1-independent manner. Interestingly, p38 inactivation had
no effect on PARP following 50 µM DA stimulation; however, once the D1 receptors were
blocked with SCH-23390, then p38 appeared to play a pro-apoptotic role (see Tables 1 and 2).
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Cleaved CASP3

SKF-38393
DA
+
SCH-23390
DA
+
SB203580
SKF-38393
+
SB203580
DA
+
SCH-23390
+
SB203580

Cleaved PARP

vs. 25 µM DA

vs. 50 µM DA

vs. 25 µM DA

vs. 50 µM DA

↔

↔

↑

↑

↓

↔

↓

↓*

↓*

↔

↓*

↔

↑*

↑*

↑↑*

↑↑*

↓↓*

↓↓*

↓↓*

↓↓*

Table 1: The Direction of Change in Markers of Apoptosis in Response to Dopamine is
Influenced by the Mechanism Through Which p38 is Activated
Given that caspase 3 cleavage (Cleaved CASP3) and PARP cleavage (Cleaved PARP) are
increased following inhibition of p38 following dopamine receptor stimulation, then it is plausible
that the phosphorylation of p38 serves a protective role when it is stimulated by the D1 receptor.
Conversely, given that caspase 3 cleavage (Cleaved CASP3) and PARP cleavage (Cleaved PARP)
are increased following inhibition of p38 following blockade of the D1 receptor, then it is plausible
that the phosphorylation of p38 serves a deleterious role when it is activated by dopamine in a
manner independent of the D1 receptor. * at least p ˂0.05 compared to dopamine; arrows without
* indicate trend in change; DA (dopamine), SB203580 (P-p38 inhibitor), SCH-23390 (D1
antagonist), SKF-23390 (D1 agonist).
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vs. 25 µM DA
Cl. CASP3

SKF-38393
DA
+
SCH-23390
DA
+
SB203580
SKF-23390
+
SB203580
DA
+
SCH-23390
+
SB203580

vs. 50 µM DA

Cl. PARP

Cl. CASP3

Cl. PARP

↔

↑

↔

↑

↓

↓

↔

↓*

↓*

↓*

↔

↔

↑*

↑↑*

↑*

↑↑*

↓↓*

↓↓*

↓↓*

↓↓*

Table 2: Difference in Dopamine Concentration Influences Whether p38 Phosphorylation
Provides a Protective or Deleterious Response
Integrating the above table helps to discern if p38 phosphorylation is protective or deleterious at
different concentrations of dopamine. A concentration of 25 µM DA has lower expression of
apoptotic cleavage markers when p38 is inhibited, while concentrations of 50 µM DA are
unchanged. This pattern of apoptotic cleavage most closely mimics that seen in the dopamine
receptor independent activation pathway; thus, it is plausible that lower concentration of 25 µM
DA operates mostly through receptor independent pathways. The opposite is observed for the
higher concentration of 50 µM DA which operates similarly to cleavage patterns seen in D1
receptor stimulation.
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Active P-p38
(without
SB203580)
Non-Active
P-p38
(with SB203580)

D1 (SKF-38393)

Non-D1 (DA + SCH-23390)

Cl. CASP3

Cl. PARP

Cl. CASP3

Cl. PARP

↔

↑

↔

↓*

↑*

↑↑*

↓↓*

↓↓*

Table 3: p38 Phosphorylation Mediates Either an Adaptive or Apoptotic Response Which
is Determined by the Presence or Absence of D1 Receptor Stimulation
Inactivation of p38 exacerbated caspase 3 and PARP cleavage when the D1 receptor was
stimulated, but upon receptor blockade with SCH-23390 the inhibition of p38 led to protection
against caspase 3 and PARP cleavage. * p ˂0.001 compared to dopamine; arrows without *
indicate directional trend of change; Cl. CASP3 (cleaved caspase 3), Cl. PARP (cleaved PARP),
DA (dopamine), SB203580 (P-p38 inhibitor), SCH-23390 (D1 antagonist), SKF-23390 (D1
agonist).
The findings in Figures 21 and 22 support a dichotomous role for p38 activation in SKN-MC. We found a difference in CASP3 cleavage that was dependent upon D1-mediated vs.
non-D1-mediated DA stimulation (Figures 16 and 18). Figures 21 and 24 demonstrate that p38
inhibition had an effect on CASP3 cleavage which mimicked that seen with PARP analysis
(Figures 22 and 25) wherein p38 inactivation was deleterious following D1 stimulation and
protective after D1 blockade. The findings from 50 µM DA samples were compelling in that p38
inactivation exacerbated CASP3 cleavage when the D1 receptors were available for binding, but
upon receptor blockade with SCH-23390, the role of p38 transposed and its inhibition led to
complete protection against CASP3 cleavage (Figure 24; see Table 3). The findings clearly
implicate p38 phosphorylation as a mediator of DA-induced cellular adaptation versus apoptosis
depending on its upstream activation. We propose that the D1-mediated increase in cell death
following p38 inhibition occurred through recruitment of an additional apoptotic pathway i.e.,
activation and cleavage of CASP3. As shown, inhibition of p38 phosphorylation resulted in a
84

significant increase in CASP3- and PARP-cleavage following SKF-38393 treatment suggesting
that p38 may serve a protective function when stimulated exclusively through D1. Conversely,
simultaneous inhibition of D1 and p38 worked in a synergistic fashion to completely stabilize
CASP3 from cleavage, thus suggesting that p38 activation through redox-sensitive mechanisms,
such as DA autoxidation, may have a causal role in CASP3 cleavage. The disparity in results
between 25 and 50 µM DA treatments may reside in the extent to which the D1 receptor is
activated. It is plausible that the reduced concentration of 25 µM DA does not confer sufficient
D1 agonistic capability, due to rapid DA oxidation, to elicit the protective effects of p38 seen at
50 µM concentration. The majority of p38 phosphorylation may be, therefore, in response to DA
autoxidation resulting in activation of the pro-apoptotic p38 signaling cascade. Similarly, the
pharmacodynamic properties of SKF-38393 offer ~1000 times greater affinity for D1 than DA
(Missale et al., 1998); consequently, the lower 25 µM concentration of SKF-38393 provides
substantially more D1 stimulation than does the same concentration of DA, and thus activates the
p38-protective pathway (see Table 3).
Only a limited amount of research on the role of stimulant-induced p38 expression in
neurons is available. One study examined rat primary cortical neurons following treatment with
methamphetamine and found p38 inhibition with SB203580 exacerbated apoptosis and suggested
p38 phosphorylation served an anti-apoptotic role in MA-induced neurotoxicity (Huang et al.,
2009). Another study reported neuronal protection in nematodes with a genetic mutation of the
p38 signaling pathway following treatment with the DA oxidation metabolite 6hydroxydopamine (Schreiber & McIntire, 2011). The results from the latter study are
comparable to our findings in Figure 25 whereby we demonstrate a pro-apoptotic role for p38
when activated by DA through a non-D1 mediated manner, such as DA oxidation. We
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hypothesize that a difference in stimuli results in activation of separate isoforms of p38. There
are four isoforms of p38, and they may have dual-roles in cancer, ischemia-reperfusion, and
other pathologies (Pramanik et al., 2003; Risco & Cuedna, 2012; Tanno et al., 2003). The
antibody we used reacts with multiple p38 isoforms, thus future research should determine if DA
activates alternate p38 isoforms depending on D1 stimulated vs. non-D1 mediated mechanisms.
In order to investigate potential downstream targets of p38 that may modulate CASP3
cleavage, we examined the phosphorylation status of heat shock protein 27 (HSP27) in SK-NMC. Heat shock protein 27 is a known target of p38, and its activation inhibits components of
apoptosis (Mearow et al., 2002; Shi et al., 2011). Activation of HSP27 attenuates apoptosis
through stabilization of CASP3 (Pandey et al., 2000; Parcellier et al., 2003) and inhibition of
cytochrome c-mediated activation of caspases (Bruey et al., 2000). Figure 26 shows a significant
increase in HSP27 phosphorylation following treatment with 25-50 µM of the D1 agonist SKF38393 as well as 50 µM DA, but not 25 µM DA. The increase in HSP27 phosphorylation was
significantly attenuated by pre-treatment with the p38 inhibitor SB203580. The results show that
HSP27 is phosphorylated following D1 stimulation in a manner dependent on p38 activation.
Integration of Figures 21 and 22 suggests that D1-mediated p38 activation offers protection from
CASP3 through recruitment of HSP27. Furthermore, HSP27-mediated protection does not occur
through an inhibition of AIF release from the mitochondria (Bruey et al., 2000); thus our
hypothesis that D1-stimulated apoptosis occurred through AIF activation is plausible. Although
research on stimulant-induced HSP27 is sparse, one study reported increased expression of
hspb1, the gene that codes for HSP27 protein, in rat striatum following 2-4 h treatment with 2040 mg/kg MA (Jayanthi et al., 2009). The authors speculated the increase in hspb1 was a
neuroprotective response to MA administration. Future studies should be aimed at further
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understanding the role of HSP27 in DA toxicity, such as analyzing apoptotic markers following
DA treatment in cells overexpressing HSP27.
In addition to HSP27, we examined another downstream target of p38, AP-1. This
protein is a known modulator of cell survival and death (Shaulian & Karin, 2001; 2002), and MA
injections enhance expression of transcription factors from the AP-1 family in mouse brain
(Cadet et al., 2001; Krasnova & Cadet, 2009) as well as increase AP-1 DNA binding in mouse
striatum (Flora et al., 2002). Additionally, we have shown enhanced AP-1 reporter activity
following treatment with 25-50 µM DA in our system (Figure 14). In order to determine the
mechanisms responsible for AP-1 activation following DA treatment we evaluated the role of
p38 in specific D1 stimulation and DA-mediated D1-independent effects on AP-1 reporter assays.
Figure 27 shows that 50 µM DA-induced AP-1 luciferase activity was significantly decreased
following treatment with the p38 inhibitor SB203580. The results from Figure 27 suggest that
DA-induced AP-1 is dependent upon p38 activation. We have evidence for two pathways by
which p38 may be activated following treatment with DA. Figure 28A displays an absence of
AP-1 activity following treatment with 0-100 µM of the D1 agonist SKF-38393 despite
significant enhancement with the same concentrations of DA. Conversely, Figure 28B shows
that a D1-independent mechanism of DA treatment significantly increased AP-1 activity as
evidenced by no significant change in AP-1 luciferase activity compared to DA following D1
blockade with SCH-23390. The results from Figure 28A and B demonstrate that AP-1 is
activated by DA in a manner independent of D1 receptor stimulation, such as DA oxidation. Our
findings from Figure 25 suggest that the D1-independent activation of p38 enhances apoptosis in
this system. Given that AP-1 is mediated through this pathway of p38 activation (Figure 27), we
hypothesize that AP-1 activation is involved in DA-induced SK-N-MC cell death.
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Activator Protien-1 exists as a dimer composed of members from the AP-1 family such
as: c-Jun, c-Fos, ATF, junB, and junD (Shaulian & Karin, 2001; 2002). Since c-Fos has long
been implicated as a precursor to neuronal apoptosis (Smeyne et al., 1993; Shaulian & Karin,
2001), we examined AP-1 activity after transiently transfecting a dominant negative to c-Fos
called A-Fos (Olive et al., 1997) as shown in Figure 29A. The dominant negative protein
significantly decreased AP-1 reporter activity thereby suggesting c-Fos is a component of DAactivated AP-1 in SK-N-MC. A parallel experiment examining DA-induced PARP cleavage
after A-Fos transfection showed that the knock-down of AP-1 was sufficient to prevent PARP
fragmentation (Figure 29B). These findings suggest that AP-1 is a c-Fos dependent mediator of
DA-induced apoptosis in SK-N-MC, which fits with our hypothesis that the D1-independent
activation of p38 is a pro-apoptotic pathway. In opposition to our findings that AP-1 is proapoptotic in a model of MA-induced neurotoxicity, studies with c-Fos heterozygous mice
showed an increase in MA-stimulated degeneration when compared to their wild type controls
and led the authors to suggest a protective role for AP-1 transcription (Deng et al., 1999). The
markers used in this study, however, were decreased DAT binding and reduced tyrosine
hydroxylase activity, both of which are markers of presynaptic toxicity rather than postsynaptic
neurotoxicity. In support of our work, a 2008 study reported inhibition of MA-induced JNK
phosphorylation decreased cell death in SH-SY5Y cells. The authors of this study suggest that
protection was through inhibition of JNK-mediated c-Jun activation; and therefore concluded
that downstream AP-1 transcription may be detrimental to cell viability (Wang et al., 2008)—
which is in accordance with our studies. Since SH-SY5Y cells contain DAT and do not possess
DA receptors this model more appropriately served as a study for pre-synaptic terminal
degeneration as opposed to postsynaptic apoptosis. Methamphetamine-induced terminal PARP
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fragmentation (Jayanthi et al., 2004) and deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) staining (Zhu et al., 2006) have been used as markers for striatal postsynaptic
apoptosis in mice. One study examined TUNEL staining and PARP fragmentation within the
striatum of c-Jun heterozygous mice following 30 min to 3 days treatment with 40 mg/kg MA.
The report showed that c-Jun heterozygotes were protected against MA-induced PARP
fragmentation and had significantly less TUNEL-positive cells within the striatum (Deng et al.,
2002b). The authors suggest that MA-induced striatal AP-1 activation is pro-apoptotic, a
conclusion consistent with our findings.
We hypothesize that D1-independent mechanisms of DA treatment, such as DA
oxidation, are responsible for activation of AP-1 as its activation is sensitive to alteration in
redox-status such as elevated reactive oxygen/nitrogen species (Flora et al., 2002; Krasnova &
Cadet, 2009). We have also provided evidence that p38 and c-Fos are involved in DA-mediated
activation of AP-1 in SK-N-MC. We are the first to show that DA stimulation activates AP-1
through a p38-dependent and D1-independent manner in SK-N-MC. We are also the first to
report that DA-induced AP-1 contains c-Fos and is pro-apoptotic in this system.
Figure 30 shows our hypotheses regarding mechanisms responsible for DA-induced
apoptosis in SK-N-MC based on a consolidation of findings from the current research. We
conclude that DA treatment leads to apoptosis through two distinct mechanisms. The first
mechanism occurs through stimulation of the D1 receptor. Dopamine D1 stimulation leads to
activation of AIF and subsequent PARP fragmentation in a caspase-independent manner. We
propose that D1-stimulated p38 activates HSP27, which then stabilizes CASP3 in an attempt to
mount a protective response. The second mechanism of apoptosis involves D1-independent
effects of DA, such as DA oxidation. We speculate that p38 is activated through a change in
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intracellular redox status from DA-mediated RO/NS generation. When p38 is activated through
this pathway it serves as a pro-apoptotic mediator by activating AP-1 in a c-Fos dependent
manner with resultant CASP3 and PARP cleavage. We are the first to report a dual-role for p38
in DA-induced neurotoxicity, and thus we deem MAPK p38 as the “molecular switch” between
adaptation and apoptosis in this system. We used these findings to develop two separate ways to
prevent DA-induced apoptosis in this model by: 1) co-inhibiting D1 receptor stimulation and
p38, or 2) employing a c-Fos dominant negative to block AP-1 activity.
The findings from our study offer mechanistic insight into clinical and translational data
involving D1 postsynaptic striatal apoptosis following stimulant exposure wherein we identified
key participants of associated neurotoxic signaling pathways. The results also demonstrated
potential neurotoxic side-effects in the use of D1 agonists to combat craving and relapse.
Toxicological studies should be conducted on such compounds before further research is
continued. Our identification of two unique ways to prevent DA-induced apoptosis could serve
as a starting point for the development of pharmacological intervention against the cycle of MAinduced neurotoxicity.
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Figure 29: The p38-Mediated Molecular Switch
The initial route of p38 activation by dopamine (DA), either through generation of reactive
oxygen species (ROS) or DA stimulation of the D1 receptor (D1) determines the downstream
effect of p38. If it is activated by ROS, then p38 triggers both the cleavage of caspase 3 (cl.
CASP3) and transcription of cFos-containing Activator Protein-1 (AP-1). These events
culminate in cleavage of poly(ADP-ribose) polymerase (cl. PARP) and subsequent cellular
apoptosis. If p38 is activated by D1 stimulation, then CASP3 is stabilized by p38-modulated heat
shock protein 27 (Hsp27) expression. Despite the stabilization of CASP3, we hypothesize that
D1 stimulation triggers caspase-independent Apoptosis Inducing Factor (AIF), and it is through
this mechanism that D1 stimulation results in cl. PARP and apoptosis. Solid lines are
representative of data generated in this work. Dashed lines have not been proven in this study
but are representative of working hypothesis and targets for future work.
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CHAPTER 4
GLOBAL DISCUSSION AND FUTURE DIRECTION
Global Discussion
The goal of this mechanistic-based study was to identify specific cellular macromolecules
involved in DA-induced neurotoxicity that could potentially serve as targets for pharmacological
intervention aimed at attenuating MA-associated striatal toxicity. By utilizing basic biomedical
science, we developed an in vitro model to investigate molecular mechanisms responsible for the
long-term, possibly irreversible neurotoxicity seen following MA abuse. Our hopes were that
this research and associated findings would provide information relevant to the development of
possible therapeutic options, including but not limited to the following: 1) macromolecular
changes associated with enhanced reactive oxygen/nitrogen species and the effect of antioxidant
supplementation, 2) identification of specific enzymes that contribute to or protect against
MA/DA toxicity, 3) modulation of pro-apoptotic cell-signaling and gene expression following
DA exposure, as well as 4) the role of D1-mediated vs. non-D1-mediated DA stimulation in
apoptosis and associated downstream signaling.
Through this work we collected molecular evidence for pro-(nitro)oxidative protein
changes within SK-N-MC following 25 and/or 50 µM DA treatment. Previous studies in this
model reported a DA-facilitated increase in nitrite levels as well as attenuation of cytotoxicity
following antioxidant supplementation (Chen et al., 2003; 2004, Moussa et al., 2006). We are
the first, however, to show protein alterations consistent with an environment rich in RO/NS
following exposure to [DA] equivalent to that seen after MA use. We propose that DA-mediated
activation of iNOS contributes to the enhanced (nitro)oxidative stress; and thereby providing
support for the role of iNOS >> nNOS in MA/DA-induced RO/NS production (Itzhak et al.,
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2000; Chen et al., 2003; reviewed in Kita et al., 2003). Although studies demonstrate cell death
following 16-24 h of DA treatment with concentrations as low as 50 µM (Chan et al., 2007;
Chen et al., 2003; Moussa et al., 2006), we are the first to report evidence of apoptosis after
exposure to half of the lowest reported concentration (25 µM); and we are the first to
demonstrate that apoptosis occurred, at least in part, through the mitochondrial-mediated
pathway involving CASP9 cleavage in SK-N-MC. Given the evidence for RO/NS and
mitochondrial-mediated apoptosis in DA-treated SK-N-MC, we assessed the expression and
activity of the mitochondrial, antioxidant enzyme MnSOD. Studies report a protective role for
MnSOD overexpression in MA-induced apoptosis (Maragos et al., 2000), but we are the first to
establish that following 50 µM DA treatment in a model of methamphetamine neurotoxicity: 1)
MnSOD expression is enhanced, 2) despite an elevation in MnSOD expression there is not a
concurrent increase in activity, and 3) MnSOD is nitrated.
We identified several key proteins involved in DA-mediated signaling within SK-N-MC.
Conflicting reports create an uncertain picture of the individual involvement of the mitogen
activated protein kinases in this system (Chan et al., 2007; Chen et al., 2004; Zhen et al., 1998).
We observed p38 and ERK1/2 phosphorylation following 25-50 and 50 µM DA, respectively,
without noting JNK phosphorylation after 6 h. We are the first to report activation of p38
through both D1-dependent and DA-mediated, D1-independent mechanisms. Further, we
postulate that p38 is the “molecular switch” of DA-stimulated SK-N-MC cells based on its
modulation of caspase 3 stabilization versus caspase 3 cleavage following D1 stimulation or nonD1 activation, respectively. We examined two transcription factors, NFκB and AP-1 known not
only for their regulatory role in iNOS and MnSOD expression, but also for their activation
following ROS-derived neuronal injury (Alderton et al., 2001; Flora et al., 2002; Kiningham et
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al., 1997; Pautz et al., 2010). This is the first report to demonstrate that NFκB reporter activity
was not increased after 0-100 µM DA treatment, which is above the EC50 of 75 µM DA for D1
receptors in SK-N-MC (Moussa et al., 2006). Unlike NFκB, AP-1 reporter activity was
significantly increased following a 6 h treatment of SK-N-MC cells with 25-100 µM DA.
Additional studies allowed us to be the first to report that in this model AP-1 is: 1) activated
through a non-D1-mediated pathway following DA stimulation, 2) dependent upon upstream p38
phosphorylation, and 3) a heterodimer containing cfos (Shaulian & Karin, 2001; 2002).
Although the above findings further the understanding of MA/DA-mediated mechanisms
of neurotoxicity, perhaps our most important contribution lies in the discovery of multiple ways
to prevent DA-induced apoptosis in our model. We identified three ways to prevent apoptosis in
this model of DA-induced neurotoxicity which mimics that caused by MA abuse. The current
study shows that by: 1) providing exogenous SOD supplementation prior to treatment, 2)
simultaneously blocking the D1 receptor and p38 phosphorylation, or 3) using a dominant
negative to cfos we can prevent PARP fragmentation following 24 h treatment with 50 µM DA.
The original goal in the present study was to identify intracellular processes that may be
responsible for the stereotyped neurotoxicity and functional impairment sustained by MA
abusers. The implications of these findings may be extended to translational studies; and
ultimately into clinical research. As stated previously, taking into account that the neurotoxicity
experienced by MA abusers has negative, long-term functional sequelae with no effective
treatment (Barr et al., 2006; Brackins et al., 2011; Chang et al., 2002; Salo et al., 2005; 2007;
Volkow et al., 2001a, b), then perhaps the best “treatment” would be during MA abuse to prevent
these from occurring.
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Future Direction
Integrating the findings from this current work, it appears that SK-N-MC cells execute a
dual response following DA treatment. The initiation of apoptosis clearly suggests SK-N-MC
cells undergo programmed cell death in response to noxious stimuli. Conversely, an adaptive
response is also initiated within SK-N-MC as evidenced by increased MnSOD protein
expression, phosphorylation of HSP27, and stabilization of caspase 3. We decided to determine
the status of HSP32, otherwise known as heme oxygenase-1 (HO-1), given that HO-1 expression
is considered a neuroprotective response (Jazwa and Cuadrado, 2010; reviewed in Maines et al.,
2000;) and is upregulated following DA stimulation or (nitro)oxidative stress (Calabrese et al.,
2004; Naughton et al., 2002; reviewed in Schipper, 2004).
Figure 31 shows time-dependent expression of HO-1 in SK-N-MC following 0-50 µM
DA treatment for 8, 16, and 24 h. The magnitude of HO-1 protein upregulation at 12-24 h
prompted the investigation of potentially harmful consequences from HO-1 overexpression.

Figure 30: Dopamine Increases Heme Oxygenase 1 Expression in a Time-Dependent
Manner
Western analysis of heme oxygenase-1 (HO-1; at 37 kDa) following 8, 16, or 24 h treatment with
0-50 µM DA. Heme oxygenase-1 expression was noted within 8 h of DA treatment. A marked
increase in protein expression was observed between 8-16 h DA treatments. The figure is
representative of findings repeated at least twice.
Reports suggest that enhanced HO-1 activity may contribute to and exacerbate, rather
than ameliorate, neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease,
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Huntington’s disease, and multiple sclerosis (Mehindate et al., 2001; Schipper et al., 2000, 2006,
2009; Song, L. et al., 2007; Song, W. et al., 2006;). Interestingly, the Hmox1 gene, which codes
for the HO-1 protein, is induced in rat striatum after 2 h MA treatment (Jayanthi et al., 2009), but
the study did not address if the upregulation of HO-1 is protective or deleterious. A study using
cortical neuron/glial co-cultures reported that p38 inhibition decreases MA-induced HO-1
expression and subsequently exacerbates toxicity when compared to MA treatment alone. The
study also showed inhibition of HO-1 activity by tin protoporphyrin IX increased MA-induced
neurotoxicity (Huang et al., 2009).
Although these results suggest a protective role for HO-1, caution must be taken when
analyzing data subsequent to p38 inhibition. As we have shown, p38 may play multiple roles
within the same system; thus the decrease in HO-1 expression may not be causal for the
increased toxicity noted in the study, rather it may be from inhibition of a p38-mediated
protective pathway following MA administration. Likewise, carbon monoxide (CO) is a byproduct of HO-1-facilitated heme breakdown as well as an upstream modulator of p38
phosphorylation (reviewed in Chung et al., 2008); therefore, the attenuation in HO-1 activity by
tin protoporphyrin IX may indirectly hinder any protective effects from p38 signaling through
decreased CO production. In opposition to the last two points, MA-induced HO-1 expression
may be neuroprotective as suggested (Huang et al., 2009).
Based on preliminary data generated in our laboratory, we hypothesize the existence of a
“feed-forward” loop between HO-1 and iNOS expression that leads to MnSOD inactivation and
generation of massive (nitro)oxidative stress. The abundance of RO/NS overwhelms the cell’s
antioxidant capacity and neuronal death ensues (see Figure 32). We have established that in this
cell system: 1) DA generates RO/NS; 2) both HO-1 and iNOS are upregulated upon DA

96

treatment in a time-sensitive manner; 3) footmarkers for peroxynitrite, such as 3-nitrotyrosine,
are present following DA administration; 4) MnSOD is nitrated and fails to mount an adaptive
response; 5) cellular apoptosis occurs as evidenced by stereotypical, microscopic, morphological
appearance and PARP cleavage. The centerpiece to this hypothesis is the relationship of HO-1
activity to iNOS protein expression. Heme oxygenase-1 is upregulated by RO/NS and DA
(reviewed in Schipper, 2004), but its modulation is particularly sensitive to iNOS-generated RNS
(Datta and Lianos, 1999; Kitamura et al, 1998; Immenschuh et al., 1999). Furthermore, CO, a
known by-product of HO-1 mediated heme breakdown, upregulates iNOS expression (Calabrese
et al., 2004). As depicted in Figure 32, it is plausible that HO-1 has a deleterious role through its
relationship with iNOS regulation in this cell system.
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Figure 31: Proposed Mechanism of Action of Methamphetamine Neurotoxicity
Methamphetamine (MA) administration releases supraphysiological concentration of dopamine
(DA) from the striatum. Heme oxygenase-1 (HO-1) expression is enhanced by DA, and its
enzymatic by-product, CO, upregulates iNOS protein. The increased iNOS activity produces
nitric oxide (NO•) that can: 1) combine with superoxide radicals (O2•‾) from DA autoxidation and
form highly reactive peroxynitrite (ONOO‾), and 2) further upregulate HO-1 resulting in greater
CO production and enhanced iNOS expression. The resulting ONOO‾ renders MnSOD
susceptible to nitration and subsequent inactivation, thus the system becomes overwhelmed with
(nitro)oxidative stress and neuronal apoptosis ensues. Given the cyclic, feed-forward system
between HO-1 and iNOS, we hypothesize that inhibition of HO-1 or its activity may avert MAmediated DA neurotoxicity.
Future studies in our laboratory will be aimed at determining the role of HO-1 in DAinduced SK-N-MC toxicity as well as the modulation of its upstream signaling. Poly (ADPribose) polymerase fragmentation will serve as the indicator for apoptosis with and without the
use of a blood brain barrier-permeable HO-1 inhibitor, such as Sn (IV) mesoporphyrin IX,
following DA treatment. Analysis of HO-1 expression following treatment with a D1 agonist,
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co-treatment with DA and a D1 antagonist, MAPK inhibitors, or A-Fos will provide information
critical to understanding its DA-mediated signaling.
In regard to every past or present finding from this research, the ultimate goal is to conduct
similar studies in vivo using a murine model. The first step will be to gather initial data on protein
alterations within the striatum of MA-exposed mice such as: nitro(oxidative) changes, verification
of apoptosis in the system, and up/down regulation of key enzymes. If the results from the MA
treated murine studies reveal nitration of MnSOD, then we would administer MnSOD mimetics
or other antioxidant treatment prior to MA and then reassess MnSOD and neurotoxic parameters.
If HO-1 is expressed in the striatum following MA administration, then pre-treatment with a HO1 inhibitor and analysis of neurotoxic parameters would be appropriate to evaluate if HO-1 is
protective or deleterious. Studies in HO-1 knockout mice, to which we have access, would also
help identify the role of MA-induced HO-1 expression. The findings from the murine research
would hopefully serve as a bridge to translational studies--perhaps in primates--and with an
ultimate goal of reaching clinical relevance.
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APPENDIX A: APPROVAL LETTER
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APPENDIX B: ABBREVIATIONS

•

OH—hydroxyl radical

3-NT—3-nitrotyrosine
4-HNE—4-hydroxy-2-nonenal
AIF—apoptosis-inducing factor
AMPH—amphetamine
ANOVA—analyses of data and variance
AP-1—activator protein 1
ATS—amphetamine type stimulants
CASP3—caspase 3
CASP9—caspase 9
CO—carbon monoxide
Cu/ZnSOD—copper/zinc superoxide dismutase
DA—dopamine
DAT—dopamine transporters
eNOS—endothelial nitric oxide synthase
ERK1/2—extracellular signal-related kinases 1 and 2
GAPDH—glyceraldehyde 3-phosphate dehydrogenase
H+—hydrogen ion
H2O2—hydrogen peroxide
HO-1—heme oxygenase-1
HSP27—heat shock protein 27
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HSP70—heat shock protein 70
iNOS—inducible nitric oxide synthase
JNK—c-Jun N-terminal kinase
MA—methamphetamine
MAO-A/B—monoamine oxidase A or B
MAPK—mitogen activated protein kinase
MnSOD—manganese superoxide dismutase
MTT —3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyl tetrazolium bromide
NFκB—nuclear factor kappa B
nNOS—neuronal nitric oxide synthase
NOS—nitric oxide synthase
Nrf-2—nuclear factor E2-related factor
O2—molecular oxygen
O2•−—superoxide radical
ONOO-—peroxynitrite
P-ERK 1/2—phosphorylated extracellular signal-related kinases 1 and 2
P-p38—phosphorylated p38
PARP—poly (ADP-ribose) polymerase
PEG-SOD—polyethylene glycol superoxide dismutase
RO/NS—reactive oxygen/nitrogen species
SB203580—inhibitor of p38 phosphorylation
SCH-23390—selective dopamine D1 receptor antagonist
S.E.M.—standard error of the mean
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SKF-38393—selective dopamine D1 receptor agonist
SOD—superoxide dismutase
STAT—signal transducer and activator of transcription
TNF—tumor necrosis factor
TPA—tissue plasma activator or 12-O-tetradecanoylphorbol-13-acetate or phorbol ester
TUNEL—deoxynucleotidyl transferase-mediated dUTP nick-end labeling
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